



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> C07D 277/28, 417/12, 417/06, 277/60, 277/64, 233/54, 213/38, 235/14	<b>A1</b>	<b>(11) International Publication Number:</b> WO 97/48687 <b>(43) International Publication Date:</b> 24 December 1997 (24.12.97)
<b>(21) International Application Number:</b> PCT/US97/09496 <b>(22) International Filing Date:</b> 30 May 1997 (30.05.97)  <b>(30) Priority Data:</b> 60/019,988 18 June 1996 (18.06.96) US  <b>(71) Applicant (for all designated States except US):</b> WARNER-LAMBERT COMPANY [-/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BERRYMAN, Kent, Alan [US/US]; 3211 Mc Comb, Ann Arbor, MI 48108 (US). DOHERTY, Annette, Marian [US/US]; 106 Tulip Tree Court, Ann Arbor, MI 48103 (US). EDMUNDS, Jeremy, John [GB/US]; 3957 Beech Drive, Ypsilanti, MI 48197 (US). PLUMMER, Janet, Samartino [US/US]; 8100 Huron River Drive, Dexter, MI 48130 (US).  <b>(74) Agents:</b> RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> With international search report.
<b>(54) Title:</b> PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES OF BASIC AMINO ACIDS		
<b>(57) Abstract</b>  A process for the preparation of novel keto heterocycle derivatives of basic natural and unnatural amino acids which affords products of high enantiomeric excess where a metalated heterocycle is reacted with N,O-dialkyl amide of an amino acid containing arylsulphonamide protected side chain amine in high chemical and optical yield as well as the novel compounds obtained by the process.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES  
OF BASIC AMINO ACIDS

BACKGROUND OF THE INVENTION


The present invention relates to the preparation of keto heterocycle derivatives of amino acids that have utility in the preparation of biologically active substances. These derivatives may, for example, be incorporated in inhibitors of serine proteases such as thrombin, Factor Xa, and Factor VIIa. As such these inhibitors have utility in the treatment of diseases that result from abnormal coagulation. Typical pathologic conditions include, for example, venous and arterial thrombosis, atrial fibrillation, stroke, restenosis, and recurrent myocardial infarction. These compounds are useful for preventing or treating unstable angina, refractory angina, disseminated intravascular coagulation, and ocular build up of fibrin. Since thrombin has also been demonstrated to activate a number of different cell types, these compounds are useful for the treatment or prophylaxis of septic shock and other inflammatory responses such as acute or chronic atherosclerosis. The compounds also have utility in treating neoplasia/metastasis and neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

Previously peptidyl keto heterocycles have been prepared by conversion of cyano hydrins to imino ethers derivatives and cyclisation with, for example, amino phenols to afford peptidyl-keto-benzoxazoles (Edwards PD, et al., J. Am. Chem. Soc., 114, 1854 (1992)). Alternatively addition of lithiated heterocycles to N,O-dimethyl amides of the amino acid valine has been shown to proceed in good chemical and


optical yield (Edwards PD, et al., J. Med. Chem.,  
 38,76 (1995)). While the N,O-dimethyl amide of  
 BOCNH-Arg(Mtr) has been used to prepare keto amides  
 (Deng J, et al., Angew. Chem. Int. Ed. Engl.,  
 33(17),1729 (1994)), and in failed attempts to prepare  
 arginals (Guichard G, et al., Pept. Res., 6,121 (1993))  
 they have not previously found use in the preparation  
 of keto heterocycle basic amino acid derivatives.

# SUMMARY OF THE INVENTION

Accordingly, a first aspect of the present  
 invention is a novel process for the preparation of a  
 compound of Formula I (D(-)) or Formula I (L(+))



wherein R<sup>1</sup> is



wherein X is O,

S, or

NR<sup>5</sup> wherein R<sup>5</sup> is H,

alkyl,

alkenyl,

alkynyl,

cycloalkyl,

cycloalkylalkyl,

aryl, or

-3-

arylalkyl,

n is zero or an integer of 1 to 4, and  
 $R^4$  is H,

halogen,

$NHR^5$  wherein  $R^5$  is as defined above,

$NR^5(R^{5a})$  wherein  $R^5$  and  $R^{5a}$  are the same  
 or different and are as defined  
 above for  $R^5$

$OR^5$  wherein  $R^5$  is as defined above,

 $NO_2$ ,

CN,


$SO_4R^5$  wherein  $R^5$  is as defined above,

$C(=O)NR^5R^{5a})$  wherein  $R^5$  and  $R^{5a}$  are the  
 same or different and are as  
 defined above for  $R^5$ ,


$CO_2R^5$  wherein  $R^5$  is as defined above,

$C(=O)R^5$  wherein  $R^5$  is as defined above,  
 aryl, or


heteroaryl,




wherein t is zero or an integer of  
 1 to 3, and X, n, and  $R^4$  are  
 as defined above,




wherein X, n, and  $R^4$  are as defined  
 above,




wherein n and  $R^4$  are as defined  
 above,




wherein n and  $R^4$  are as defined  
 above,



wherein n and R<sup>4</sup> are as defined above,




wherein n and R<sup>4</sup> are as defined above,




wherein n and R<sup>4</sup> are as defined above;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>q</sub>-Y wherein Y is



wherein R<sup>5</sup> is as defined above, and R<sup>6</sup>, R<sup>6a</sup>, R<sup>6b</sup>, R<sup>6c</sup>, R<sup>6d</sup> are the same or different and are H, alkyl, alkenyl, alkynyl, cycloalkyl, or OR<sup>5</sup> wherein R<sup>5</sup> is as defined above,




-5-

wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above,

5


10



wherein  $p$  is zero or an integer of 1 to 2, and  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, or


15

20




wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, and  $q$  is an integer of 3 to 6,

25




wherein  $u$  is zero or an integer of one, and  $p$  and  $Y$  are as defined above,

30




wherein  $u$  and  $Y$  are as defined above,


35




wherein  $Z$  is




wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, or




wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, and wherein  $u$  is as defined above,




wherein  $u$ ,  $p$ , and  $Z$  are as defined above,



wherein  $u$ ,  $p$ , and  $Z$  are as defined above,




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as defined above,




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as defined above,




-7-




wherein  $u$ ,  $\text{R}^{5a}$ , and  $Y$  are as defined above,



wherein  $u$ ,  $\text{R}^{5a}$ ,  $\text{R}^5$  and  $Y$  are as defined above,




wherein  $u$ ,  $\text{R}^{5a}$ , and  $Y$  are as defined above, or




wherein  $u$ ,  $\text{R}^{5a}$  and  $Y$  are as defined above; and

$\text{R}^3$  is H,




wherein  $\text{R}^7$  is alkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, or aryl, or



wherein  $\text{R}^7$  is as defined above; or an addition salt thereof;

which comprises:


step (a) treating a compound of Formula IIIa (D(-)) or Formula IIIa (L(+))



IIIa (D(-))


IIIa (L(+))

wherein  $R^{3a}$  is  $CO_2R^7$ , wherein  $R^7$  is as defined above,  
or



wherein  $R^7$  is as defined above, and  
 $R^2$  is as defined above;

with an activating reagent in a solvent to afford an  
activated acyl intermediate which is treated with a  
compound of formula:




wherein  $R^8$  and  $R^{8a}$  may be the same or different  
and are  
alkyl,

cycloalkyl,


cycloalkylalkyl, or

$R^8$  and  $R^{8a}$  may be joined to form a ring of  
from 4 to 8 atoms, to afford a compound of  
Formula IIa (D(-)) or Formula IIa (L(+))



IIa (D(-))

or



IIa (L(+))


wherein  $R^2$ ,  $R^{3a}$ ,  $R^8$ , and  $R^{8a}$  are as defined above;

step (b) treating a compound of Formula IIa (D(-))  
or Formula IIa (L(+)) with a compound of Formula IV




IV

wherein M is lithium, cerium halide, titanium alkoxide, titanium halide, or magnesium halide and R<sup>1</sup> is as defined above, in a solvent to afford a compound of Formula Ia (D(-)) or Formula Ia (L(+))




wherein R<sup>1</sup>, R<sup>2</sup>, and R<sup>3a</sup> are as defined above;

15 step (c) treating a compound of Formula Ia (D(-)) or Formula Ia (L(+)) with a deprotecting reagent in a solvent to afford a compound of Formula Ib (D(-)) or Formula Ib (L(+))



25 wherein R<sup>1</sup> and R<sup>2</sup> are as defined above.

A second aspect of the present invention is a novel compound of Formula I (D(-)) or Formula I (L(+))



wherein  $R^1$ ,  $R^2$ , and  $R^3$  are as defined above; or an addition salt thereof.

5                    DETAILED DESCRIPTION OF THE INVENTION

10            In the compounds of the present invention, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, n-propyl, tert-butyl, and the like.

15            The term "alkenyl" means a straight or branched unsaturated hydrocarbon radical having from 2 to 6 carbon atoms and includes, for example, 2-butenyl, 3-methyl-3-butenyl, 1-hexenyl, and the like.

20            The term "alkynyl" means a straight or branched triple bonded unsaturated hydrocarbon radical having from 2 to 6 carbon atoms and includes, for example, 2-butyne, 3-hexyne, and the like.

25            The term "cycloalkyl" means a saturated hydrocarbon radical having from 3 to 12 carbon atoms and includes, for example, cyclopropyl, cyclopentyl, and the like.

30            The term "cycloalkylalkyl" means a cycloalkyl group attached to an alkyl group wherein "cycloalkyl" and "alkyl" are as defined above and includes, for example, cyclopropylmethyl, cyclopentylethyl, and the like.

35            The term "alkyloxy" is O-alkyl as defined above for alkyl.

             The term "aryl" means an aromatic radical which is a phenyl or naphthyl group, which may be unsubstituted or substituted by 1 to 5 substituents selected from, alkyl, alkyloxy, wherein the alkyl or alkyloxy substituents may be part of a ring occupying two

-11-

adjacent ring positions and includes, for example, dihydrobenzopyrans, benzo-1,3-dioxole, and the like.

The term "arylalkyl" means an aromatic radical attached to an alkyl radical wherein "aryl" and "alkyl" are as defined above and includes for example benzyl, and naphthylmethyl.

The term "heteroaryl" means a heteroaromatic radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzothienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl unsubstituted or substituted by 1 to 4 substituents selected from alkyl as defined above or alkyloxy as defined above, hydroxy, thiol, nitro, halogen, formyl, amino,  $\text{CONH}_2$ ,  $\text{CO}_2$ alkyl, ketone, or nitrile.

The term "halogen" means fluorine, chlorine, bromine, or iodine.

Compounds of the present invention are capable of forming acid addition salts (see for example, Berge SM, et al., Pharmaceutical Salts, Journal of Pharmaceutical Science, 66,1-10 (1977)) with inorganic acids such as for example hydrochloric acid, sulfuric acid, and the like as well as salts derived from organic acids such as for example aliphatic mono and dicarboxylic acids or aliphatic and aromatic sulphonic acids. The acid addition salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt. The free base form may be regenerated by contacting the salt form with a base.

While the free base more may differ from the salt form in terms of physical properties, such as solubility, the salts are equivalent to their respective free bases for the purposes of the present invention. Certain compounds of the present invention can exist in unsolvated form as well as solvated form including hydrated form. In general the solvated form, including hydrated form are equivalent to unsolvated form and are intended to be encompassed within the scope of the present invention. In some situations compounds of the present invention form diastereomers as a result of an additional chiral center. Therefore all stereoisomers are considered to be included in this invention.





The following table provides a list of abbreviations and definitions thereof used in the present invention.

-13-

	Abbreviation	Description
	BOC	tertiary-butylloxycarbonyl
	MTR	2,3,6-trimethyl-4-methoxybenzenesulphonyl
	PMC	2,2,5,7,8-pentamethylchroman-6-sulfonyl
5	TFA	trifluoroacetic acid
	BOP-reagent	benzotriazol-1-yloxy-tris(dimethylamino) phosphonium hexafluorophosphate
	THF	tetrahydrofuran
	EtOAc	ethylacetate
	TMEDA	N,N,N',N'-tetramethylethylenediamine
10	HMPA	hexamethylphosphoramide
	DCC	dicyclohexyl carbodiimide
	DMF	dimethyl formamide
	HF	hydrogen fluoride
	DIEA	diisopropylethylamine
15	r.t.	room temperature
	Phe	phenylalanyl
	Pip	pipecolyl
	Arg	arginyll or arginine
	MOT	mean occlusion time
20	aPTT	activated partial thromboplastin time
	TT	thrombin time
	MS(ES)	mass spectrometry(electro spray)
	MS(CI)	mass spectrometry(chemical ionization)
	MS(APCI)	mass spectrometry(atmospheric pressure CI)
25	NMM	N-methylmorpholine
	IBCF	iso-butyl chloroformate
	nBuLi	n-butyl lithium
	HCl	hydrogen chloride
	NH <sub>4</sub> Cl	ammonium chloride
30	PMC-Cl	2,2,5,7,8-pentamethylchroman-6-sulfonyl chloride
	NaHSO <sub>4</sub>	sodium hydrogen sulfate
	AcOH	acetic acid
	PD/C	palladium on carbon
	NaOH	sodium hydroxide
35	PtO <sub>2</sub>	platinum oxide
	<sup>1</sup> H NMR	proton magnetic resonance
	DMSO	dimethylsulfoxide
	CDCl <sub>3</sub>	deuteriochloroform

40           The process of the present invention in its first aspect is outlined in Scheme I.



SCHEME I





-15-

A compound of Formula III (D(-)) or Formula III (L(+))



wherein  $R^5$  is H,

alkyl,

alkenyl,

alkynyl,

cycloalkyl,

20 cycloalkylalkyl,

aryl, or

arylalkyl, and

$R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are the same or different and are

25 H,


alkyl,

alkenyl,


alkynyl,

cycloalkyl, or


30  $OR^5$  wherein  $R^5$  is as defined above,



wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above,




10 wherein  $p$  is zero or an integer of 1 to 2,  
 $R^5$  and  $R^{5a}$  are the same or different and are as defined above or  $R^5$ , and  $R^6$ ,  $R^{6c}$  and  $R^{6d}$  are as defined above, or




20 wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above,

$q$  is an integer of 3 to 6,




wherein  $u$  is zero or an integer of one, and  $p$  and  $Y$  are as defined above,




wherein  $u$  and  $Y$  are as defined above,


-17-




wherein Z is




wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, or




wherein p,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, and wherein u is as defined above,




wherein u, p, and Z are as defined above,




wherein u, p, and Z are as defined above,




wherein u,  $R^{5a}$ , and Y are as defined above,




wherein u, R<sup>5a</sup>, and Y are as defined above,




wherein u, R<sup>5a</sup>, and Y are as defined above,



wherein u, R<sup>5a</sup>, R<sup>5</sup>, and Y are as defined above,



wherein u, R<sup>5a</sup>, and Y are as defined above, or



wherein u, R<sup>5a</sup>, and Y are as defined above; and


R<sup>3a</sup> is -CO<sub>2</sub>R<sup>7</sup> wherein R<sup>7</sup> is alkyl,

cycloalkyl,

cycloalkylalkyl,

arylalkyl, or

aryl, or




wherein R<sup>7</sup> is as defined above;


is treated with an activating reagent such as, for example, oxalyl chloride, thionyl chloride, diisopropyl carbodiimide, dicyclohexyl carbodiimide, 1,1'-carbonyl-diimidazole, 2-chloro-1-methylpyridinium iodide, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydro-quinoline, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium

-19-

hexafluorophosphate, bromo-tris-pyrrolidino-phosphonium  
 hexafluorophosphate, 2-(1H-benzotriazole-1-yl)-  
 1,1,3,3-tetramethyluronium tetrafluoroborate,  
 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide,  
 5 BOP-reagent, alkyl chloroformate, and the like in a  
 solvent, such as, for example, ethyl acetate,  
 tetrahydrofuran, methylene chloride, and the like at a  
 temperature of about -78°C to about 25°C, to afford an  
 activated acyl intermediate which is directly treated  
 10 with a compound of formula



wherein  $\text{R}^8$  and  $\text{R}^{8a}$  may be the same or different and are  
 15 alkyl,  
 cycloalkyl,  
 cycloalkylalkyl, or  
 $\text{R}^8$  and  $\text{R}^{8a}$  may be joined to form a ring of from  
 4 to 8 atoms (or salt thereof and base) to afford a  
 20 compound of Formula IIa (D(-)) or Formula IIa (L(+))



wherein  $\text{R}^2$ ,  $\text{R}^{3a}$ ,  $\text{R}^8$ , and  $\text{R}^{8a}$  are as defined above.

Preferably, the reaction is carried out in  
 isobutylchloroformate in the presence N-methyl-  
 morpholine in methylene chloride at about -15°C to  
 about 25°C. The N,O-dialkylhydroxylamine, i.e.,


35  $\begin{array}{c} \text{R}^8 \\ \diagup \\ \text{HN} \diagdown \text{O} \diagup \text{R}^{8a} \end{array}$ , is preferably N,O-dimethylhydroxyl amine.

A compound of Formula IIa (D(-) or Formula IIa (L(+)) is treated with a compound of Formula IV



IV

wherein M is lithium, cerium halide, titanium alkoxide, titanium halide, or magnesium halide and  $R^1$  is



wherein X is O,

S, or

$NR^5$  wherein  $R^5$  is as defined above,

n is zero or an integer of 1 to 4, and

$R^4$  is H,

halogen,

$NHR^5$  wherein  $R^5$  is as defined above,

$NR^5(R^{5a})$  wherein  $R^5$  and  $R^{5a}$  are the same or different and are as defined above for  $R^5$ ,

$OR^5$  wherein  $R^5$  is as defined above,

$NO_2$ ,

CN,

$SO_4R^5$  wherein  $R^5$  is as defined above,

$C(=O)NR^5(R^{5a})$  wherein  $R^5$  and  $R^{5a}$  are the same or different and are as defined above for  $R^5$ ,


$CO_2R^5$  wherein  $R^5$  is as defined above,

$C(=O)R^5$  wherein  $R^5$  is as defined above,

aryl, or


heteroaryl,

5




wherein  $t$  is zero or an integer of 1 to 3, and  $X$ ,  $n$ , and  $R^4$  are as defined above,

10




wherein  $X$ ,  $n$ , and  $R^4$  are as defined above,

15




wherein  $n$  and  $R^4$  are as defined above,

20




wherein  $n$  and  $R^4$  are as defined above,

25




wherein  $n$  and  $R^4$  are as defined above,

30




wherein  $n$  and  $R^4$  are as defined above,

in a solvent such as, for example, diethyl ether, tetrahydrofuran, and the like or a nonethereal solvent which does not react with a compound of Formula IV, such as methylene chloride and the like, at about  $-78^{\circ}\text{C}$  to about  $25^{\circ}\text{C}$  to afford a compound of Formula Ia (D(-)) or Formula Ia (L(-))



wherein  $\text{R}^1$ ,  $\text{R}^2$ , and  $\text{R}^{3a}$  are as defined above.  
 Preferably, M is lithium, the solvent is THF, and the  
 use of TMEDA or HMPA is optional.

A compound of Formula Ia (D(-)) or Formula Ia  
 (L(+)) is treated with a conventional deprotecting  
 reagent (for example see "Protective groups in organic  
 synthesis" Greene TW and Wuts PGM, Wiley (1991)) known  
 to those skilled in the art of organic synthesis, in a  
 solvent such as, for example, dioxane and the like at  
 about 25°C to afford compounds of Formula Ib (D(-)) or  
 Formula Ib (L(+)).




wherein  $\text{R}^1$  and  $\text{R}^2$  are as defined above.

Preferably, a compound of Formula Ia(D(-)) or  
 Formula Ib(L(+)) wherein  $\text{R}^{3a}$  is tert-butoxycarbonyl  
 (BOC) for example, are deprotected with an acid such  
 as, for example, hydrogen chloride in dioxane at about  
 25°C to afford compounds of Formula Ib (D(-)) or  
 Formula Ib (L(+)).



-23-

Compounds of Formula Ib (D(-)) or Formula Ib (L(+))




10 wherein R<sup>1</sup> and R<sup>2</sup> are as defined above may then be reacted with activated acids to afford amides as shown in Scheme II. A typical procedure requires activation of the acid with BOP-reagent and stirring this adduct with a compound of Formula Ib (D(-)) or Formula Ib (L(+)) in DMF for 2 hours. The side chain amine

15 protecting group, which is typically Pmc or Mtr is removed by treatment with TFA at about room temperature for several hours, or alternatively by treatment with a mineral acid such as, for example, anhydrous HF, in the presence or absence of a scavenger such as, for

20 example, anisole, thiophenol, ethylmethyl sulphide, and the like.

SCHEME II





-25-

These compounds are inhibitors of the proteolytic activity of serine proteases, typically thrombin as demonstrated by in vitro and in vivo experiments.

5     In Vitro

10     The ability of compounds to act as inhibitors of thrombin catalytic activity is assessed by determination of that concentration of test substance that inhibits by 50% ( $IC_{50}$ ) the ability of thrombin to cleave the chromogenic substrate S-2238 (H-D-Phe-L-Pip-L-Arg-p-nitroanilide · 2 HCl). Typically thrombin, in 10 mM HEPES, 100 mM NaCl, 0.05% BSA, and 0.1% PEG-8000 and the test substance in DMSO are incubated for 60 minutes at room temperature. To this mixture is added S-2238 and the velocity of S-2238 hydrolysis measured by observing the intensity of absorbance at 405 nm over 5 minutes.

20     A similar protocol is followed to access the trypsin inhibitory activity of the test substances, except thrombin is replaced by trypsin and the chromogenic substrate is S2222 (N-Bz-L-Ile-L-Glu-L-Gly-L-Arg-p-nitroanilide · HCl).

Example	Structure	Thrombin IC <sub>50</sub> (nM)	Trypsin IC <sub>50</sub> (nM)
A		5	1
B		30	4350

5

#### In Vivo

The ability of compounds to affect markers of anticoagulant activity in vivo were assessed in a rat arterial model of thrombosis. This model requires injury of the rat carotid artery by the application of a FeCl<sub>3</sub> solution. Typically test substances are administered by applying a loading dose of 0.75 mg/kg plus continual infusion of 50 µg/kg/min.

In this model control MOT is 20 minutes, control aPTT is 15 s and control TT is 30 s. The fold shift in aPTT and TT are measured at a 30 minute time point.

Example	Fold Shift in MOT	Fold Shift in aPTT	Fold Shift in TT
A	2.4	3.2	13
B	>3	3.1	15

20

The following nonlimiting examples illustrate the inventors' method for preparing the compounds of the present invention.


25

-27-

## EXAMPLE 1

(S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]aminoliminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide

Step (a) Preparation of: 1,1-dimethylethyl  
(S)-[4-[[[imino] (4-methoxy-2,3,6-trimethylphenyl)sulfonyl]aminolmethyl]amino]-1-(methoxymethylamino)carbonyl]butyl]-carbamate



Boc-NH-Arg(Mtr)OH


1

To Boc-NH-Arg(Mtr)OH (6.61 g, 13.6 mmol) in dichloromethane (33 mL) at 0°C was added N-methyl morpholine (1.65 mL, 15.0 mmol) then isobutyl chloroformate (1.95 mL, 15.0 mmol). Stirred at 0°C for 30 minutes. Added N,O dimethylhydroxyl amine HCl (1.5 g, 15.4 mmol) and N-methyl morpholine (1.65 mL, 15.0 mmol). Stirred at 0°C for 45 minutes. Diluted with ethyl acetate (150 mL), washed with 1N HCl (2 x 80 mL), brine (80 mL), dried with sodium sulfate, filtered, removed solvent in vacuo, and purified with silica gel column eluted with 80% ethyl acetate in hexane to 100% ethyl acetate. Isolated 4.85 g (67.5%) of product (1) as a white foam.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): 6.52 (1H, s), 6.19 (2H, bs), 5.50 (1H, d, J = 9.0 Hz) 4.63 (1H, bs), 3.82 (3H, s), 3.72 (3H, s), 3.30 (1H, bs), 3.18 (3H, s), 3.15 (3H, s), 2.69 (3H, s), 2.61 (3H, s), 2.12 (3H, s), 1.50-1.75 (4H, m), 1.41 (9H, s).

(CI MS) M + 1 = 530, M + C<sub>2</sub>H<sub>5</sub> = 558.

Step (b) Preparation of: 1,1-dimethylethyl (S)-[4-[[imino[[[4-methoxy-2,3,6-trimethylphenyl)-sulfonylaminomethyl]amino]-1-[(2-thiazolyl)carbonyl]butyl]carbamate



To thiazole (1.95 mL, 27.5 mmol) and TMEDA (3.8 mL, 25.2 mmol, distilled from sodium) in THF (65 mL, freshly distilled from potassium) at -78°C was added nBuLi in hexane (13.7 mL, 24.7 mmol, 1.8 M) at a rate that raised the internal temperature to -50°C. Placed reaction flask in dry ice/acetonitrile bath to give an internal temperature of -41°C. Stirred for 25 minutes, cooled to -78°C. Added (1) (3.18 g, 6.0 mmol) in THF (33 mL) and stirred for 45 minutes. Poured reaction over a saturated aqueous ammonium chloride solution (200 mL) and shook vigorously. Extracted with ethyl acetate (2 × 200 mL). Combined


organic phases and washed with brine (150 mL), dried with sodium sulfate, filtered, removed solvent in vacuo, purified with silica gel column eluted with 70% ethyl acetate in hexane to 100% ethyl acetate.

Isolated 3.1 g (93%) of product (2) as a white foam.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): 8.06 (1H, d, J = 3.00 Hz), 7.73 (1H, d, J = 3.00 Hz), 6.52 (1H, s), 6.19 (2H, bs), 5.63 (1H, d, J = 8.65 Hz), 5.38-5.52 (1H, m), 3.83 (3H, s), 3.50 (3H, bs), 3.19-3.31 (1H, m), 2.68 (3H, s), 2.60 (3H, s), 2.12 (3H, s), 1.50-1.75 (4H, m), 1.42 (9H, s).

(CI MS) M + 1 = 554, M + C<sub>2</sub>H<sub>5</sub> = 582.

Step (c) Preparation of: (S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide



To (2) (3.0 g, 5.4 mmol) in dioxane (9 mL) was added ethyl methyl sulfide (2.3 mL, 25.4 mmol) then 4 M HCl in dioxane (20 mL). Stirred at room temperature for 40 minutes and a yellow, gummy precipitate formed. Decanted the supernatant. Added ethyl acetate (40 mL) and stirred the gummy precipitate to change it to a fine granular precipitate. Isolated

precipitate by filtration and washed thoroughly with ethyl acetate (150 mL) to give 3.0 g of product (3).


<sup>1</sup> NMR (d<sub>6</sub>DMSO, 400 MHz): 8.61 (3H, bs), 8.42 (2H, d, J = 3.13), 8.26 (2H, d, J = 3.13), 7.03 (1H, bs), 6.67 (1H, s), 6.50 (1H, bs), 4.95-5.05 (1H, m), 3.57 (3H, s), 3.00-3.10 (2H, m), 2.56 (3H, s), 2.47 (3H, s), 1.99 (3H, s), 1.97-2.03 (1H, m), 1.82-1.90 (1H, m), 1.40-1.60 (2H, m).

(ES MS) M + 1 = 454. [α]<sub>D</sub> = +13.45 °, (C = 2.52, MeOH).

## EXAMPLE 2

(S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]amino]-iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-ylsulfonamide

Step (a) Preparation of: 1,1-dimethylethyl (S)-[4-[[[iminomethyl(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]-aminomethyl]amino]-1-[(methoxymethylamino)carbonyl]butyl]carbamate



To Boc (L) Arg(Pmc)-OH (2.0 g, 3.7 mmol) in dichloromethane (10 mL) at 0°C was added NMM (0.45 mL, 4.0 mmol) and IBCF (0.53 mL, 4.0 mmol). Stirred for




-31-

30 minutes. Added N,O-dimethylhydroxyl amine·HCl (0.43 g, 4.4 mmol) and NMM (0.45 g, 4.0 mmol). Stirred for 45 minutes. Diluted with ethyl acetate (100 mL), washed with 1N HCl (2 × 80 mL), brine (80 mL), dried MgSO<sub>4</sub> filtered, removed solvent in vacuo, purified with silica gel column eluted with 75% ethyl acetate in hexane to give 1.67 g (77%) of product (4) as a white foam.

<sup>1</sup>H NMR (d<sub>6</sub>DMSO, 400 MHz): 7.01 (1H, d J = 8.20 Hz), 6.64 (1H, bs), 6.40 (1H, bs), 4.28-4.39 (1H, m), 3.68 (3H, s), 3.33 (3H, s), 2.97-3.10 (2H, m), 2.58 (2H, t), 2.47 (6H, s), 2.03 (3H, s), 1.77 (2H, t), 1.35-1.60 (4H, m), 1.37 (9H, s), 1.26 (6H, s).  
(CI MS) M + 1 = 584, M + C<sub>2</sub>H<sub>5</sub> = 612.

Step (b) Preparation of: 1,1-dimethylethyl (S)-[4-[[[imino[[[3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]methyl]aminol-1-[(2-thiazolyl)carbonyl]butyl]-carbamate




To thiazole (0.84 g, 11.8 mmol) and TMEDA (1.66 mL, 11.0 mmol) in THF (30 mL) at -78°C was added

nBuLi in hexane (5.4 mL, 2.0 M, 10.8 mmol). Raised temperature to -41°C, stirred for 25 minutes, cooled to at -78°C, added (4) (1.53 g, 2.62 mmol) in THF (15 mL). Stirred for 45 minutes. Quenched with saturated aqueous NH<sub>4</sub>Cl (500 mL). Extracted with ethyl acetate (2 × 300 mL). Washed organic phase with brine (180 mL), dried with sodium sulfate, filtered, removed solvent in vacuo. Purified with silica gel column eluted with 75% ethyl acetate in hexane to 100% ethyl acetate to give 1.5 g (94%) of product (5) as a white foam.

<sup>1</sup>H NMR (d<sub>6</sub>DMSO, 400 MHz): 8.27 (1H, d, J = 3.14 Hz), 8.18 (1H, d, J = 3.14 Hz), 7.39 (1H, d, J = 7.23 Hz), 6.64 (1H, bs), 6.38 (1H, bs), 5.05-5.12 (1H, m), 2.99-3.08 (2H, m), 2.57 (2H, t), 2.44 (6H, s), 2.02 (3H, s), 1.77 (2H, t), 1.42-1.58 (2H, m), 1.36 (9H, s), 1.26 (6H, s), 1.1-1.8 (2H, m).

(CI MS) M + 1 = 608.

Step (c) Preparation of: (S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]aminoliminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl]sulfonamide



-33-

To (5) (0.4 g, 0.66 mmol) in dioxane (1 mL) was added ethyl methyl sulfide (0.8 g, 10 mmol) then 4 M HCl in dioxane (3 mL). Stirred at room temperature for 15 minutes. Removed solvent in vacuo. Triturated with diethyl ether (80 mL) to give 0.35 g of a yellow powder (6).

$^1\text{H}$  NMR ( $d_6$ DMSO, 400 MHz): 8.56 (3H, bs), 8.41 (1H, d,  $J = 3.13$  Hz), 8.27 (1H, d,  $J = 3.13$  Hz), 6.90 (1H, bs), 6.45 (1H, bs), 4.95-5.05 (1H, m), 3.0-3.1 (2H, m), 2.57 (2H, t), 2.43 (6H, s), 2.02 (3H, s), 1.80-1.95 (2H, m), 1.78 (2H, t), 1.42-1.58 (2H, m), 1.26 (6H, s).


(ES MS)  $M + 1 = 507$ .

$[\alpha]_D = +12.23^\circ$ , ( $C = 2.51$ , MeOH).

### EXAMPLE 3

(R)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]aminol-  
iminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfon-  
amide

Step (a) Preparation of: 1,1-dimethylethyl (R)-[4-  
[[imino[[[4-methoxy-2,3,6-trimethylphenyl]-  
sulfonvllaminol]methyl]aminol]-1-[(methoxy-  
methylamino)carbonyl]butyl]carbamate




BOC-NH-D-Arg (Mtr) OH

To Boc-NH-D-Arg(Mtr)OH (5 g, 10.3 mmol) in dichloromethane (25 mL) at -10°C was added NMM (1.2 mL, 10.8 mmol), then IBCF (1.4 mL, 10.8 mmol). Stirred for 25 minutes then added N,O-dimethylhydroxyl amine HCl (1.1 g, 11.4 mmol) and NMM (1.25 mL, 11.4 mmol) and stirred at room temperature for 1 hour. Diluted with ethyl acetate (150 mL), washed with 1N HCl (2 x 100 mL), brine (100 mL), dried with sodium sulfate, filtered, removed solvent, purified with silica gel column eluted with 65% ethyl acetate in hexane to 100% ethyl acetate to give 4.1g (75%) of product (7) as a white foam.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): 6.53 (1H, s), 6.38 (1H, bs), 6.10 (1H, bs), 5.47 (1H, d, J = 7.23 Hz), 4.65-4.73 (1H, m), 3.83 (3H, s), 3.73 (3H, s), 3.40-3.45 (1H, m), 3.20 (3H, s), 3.15 (1H, bs), 2.71 (3H, s), 2.63 (3H, s), 2.13 (3H, s), 1.50-1.75 (4H, m), 1.42 (9H, s).

Step (b) Preparation of: 1,1-dimethylethyl (R)-[4-[[[imino][(4-methoxy-2,3,6-trimethylphenyl)-sulfonylaminomethyl]aminol-1-[(2-thiazolyl)carbonyl]butyl]carbamate




-35-

To thiazole (1.24 mL, 17.4 mmol) and TMEDA (2.5 mL, 16.3 mmol) in THF (43 mL) at  $-78^{\circ}\text{C}$  was added nBuLi in hexane (8.9 mL, 1.78 M, 15.9 mmol). Raised temperature to  $-41^{\circ}\text{C}$ , stirred for 25 minutes, cooled to at  $-78^{\circ}\text{C}$ , added (7) (2.05 g, 3.88 mmol) in THF (21 mL). Stirred for 60 minutes. Quenched with saturated aqueous  $\text{NH}_4\text{Cl}$  (250 mL). Extracted with ethyl acetate (2 x 200 mL). Washed organic phase with brine (100 mL), dried with sodium sulfate, filtered, removed solvent in vacuo. Purified with silica gel column eluted with 75% ethyl acetate in hexane to give 1.3 g (61%) of product (8) as a white foam.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz): 8.07 (1H, d,  $J = 3.00$  Hz), 7.74 (1H, d,  $J = 3.00$  Hz), 6.53 (1H, s), 6.33 (2H, bs), 6.28 (2H, bs), 5.58-5.63 (1H, m), 5.40-5.50 (1H, m), 3.83 (3H, s), 3.48-3.60 (1H, m), 3.20-3.35 (1H, m), 2.70 (3H, s), 2.61 (3H, s), 2.13 (3H, s), 1.65-1.75 (2H, m), 1.55-1.65 (2H, m), 1.43 (9H, s).

Step (c) Preparation of: (R)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)pentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide



8

9

To (8) (1.0 g, 1.8 mmol) in dioxane (7 mL) was added ethyl methyl sulfide (1 mL, 11.0 mmol) then 4 M HCl in dioxane (7 mL). Stirred at room temperature for 30 minutes. A yellow precipitate formed. Decanted supernatant. Triturated precipitate with ethyl acetate (100 mL) and diethyl ether (3 x 100 mL) to give 0.9 g of a yellow powder (9).

$^1\text{H}$  NMR ( $d_6\text{DMSO}$ , 400 MHz): 8.68 (1H, bs), 8.41 (1H, d,  $J = 2.89$  Hz), 8.26 (1H, d,  $J = 3.14$  Hz), 7.15 (1H, bs), 6.68 (1H, s), 6.55 (1H, bs), 4.95-5.05 (1H, m), 3.80 (3H, s), 3.0-3.1 (2H, m), 2.56 (3H, s), 2.47 (3H, s), 2.05 (3H, s), 1.95-2.05 (1H, m), 1.85-1.95 (1H, m), 1.40-1.57 (2H, m).


(APCI MS)  $M + 1 = 454$ ,  $2M + 1 = 907$ .

$[\alpha]_D = -13.62^\circ$ , ( $C = 2.51$ , MeOH).

#### EXAMPLE 4

(S)-2,2,5,7,8-Pentamethyl-chroman-6-sulfonic acid  
(5-amino-6-oxo-6-thiazol-2-yl-hexyl)-amide

Step (a) Preparation of: (S)-[5-tert-Butoxycarbonyl-  
amino-5-(methoxy-methyl-carbamoyl)-pentyl]-carbamic  
acid benzyl ester




-37-

See also Brady SF, et al., Bioorg. Med. Chem.,  
3(8), 1063-78 (1995).

To Boc (L) Lys (Z)-OH (5.0 g, 13.7 mmol) in  
 dichloromethane (25 mL) at -10°C was added NMM (1.7 mL,  
 14.4 mmol), then IBCF (1.95 mL, 14.4 mmol). Stirred  
 for 15 minutes then added N,O-dimethylhydroxyl amine  
 HCl (1.6 g, 15.0 mmol) and NMM (1.8 mL, 15.0 mmol) and  
 stirred at room temperature for 1 hour. Diluted with  
 ethyl acetate (180 mL), washed with 1N HCl (2 x  
 100 mL), brine (100 mL), dried with sodium sulfate,  
 filtered, removed solvent, purified with silica gel  
 column eluted with 65% ethyl acetate in hexane to give  
 5.0g (87%) of product (10) as a glass.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): 7.30-7.36 (5H, m), 5.19-5.25  
 (1H, m), 5.09 (2H, s), 4.87 (1H, bs), 4.66 (1H, bs),  
 3.76 (3H, s), 3.20 (3H, s), 3.17-3.22 (2H, bs),  
 1.60-1.80 (1H, m), 1.42-1.63 (5H, m), 1.42 (9H, s).  
 (CI MS) M + 1 = 424.

Step (b) Preparation of: (S)-[5-Amino-1-(methoxy-  
methyl-carbamoyl)-pentyl]-carbamic acid  
tert-butyl ester




To (10) (5.0 g, 11.8 mmol) in ethanol (50 mL,  
 degassed) was added 10% Pd/C (1.0 g) and then stirred

under hydrogen balloon for 18 hours. Filtered through celite. Removed solvent. Dissolved in dichloromethane (50 mL), filtered through a small pad of silica gel, washed silica with 1% to 10% methanol in chloroform, removed solvent in vacuo to give 2.75 g (80%) of product (11) as a glass.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 5.2 (1H, d), 4.70-4.85 (1H, m), 3.78 (3H, s), 3.21 (3H, s), 2.70 (2H, t), 1.78-1.84 (3H, m), 1.71-1.80 (1H, m), 1.45-1.60 (2H, m), 1.44 (9H, s).

(CI MS)  $M + 1 = 290$ .

Step (c) Preparation of: (S)-[1-(Methoxy-methyl-carbamoyl)-5-(2,2,5,7,8-pentamethyl-chroman-6-sulfonylamino)-pentyl]-carbamic acid tert-butyl ester



To (11) (0.4 g, 1.38 mmol) and Pmc-Cl (0.42 g, 1.38 mmol) was added THF (4 mL) and DIEA (0.24 mL, 1.38 mmol). Stirred at room temperature for 4 hours. Diluted with ethyl acetate (120 mL), washed with 1N HCl (80 mL), brine (80 mL), dried with  $\text{MgSO}_4$ , filtered,




-39-

removed solvent in vacuo, purified with silica gel column eluted with 45% ethyl acetate in hexane to give 0.7g (91%) of product (12).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 5.17 (1H, d,  $J = 8.92$  Hz), 4.63 (1H, bs), 4.40-4.50 (1H, m), 3.75 (3H, s), 3.19 (3H, s), 2.89 (2H, q), 2.66 (2H, t), 2.55 (3H, s), 2.54 (3H, s), 2.05 (3H, s), 1.83 (2H, t), 1.60-1.70 (1H, m), 1.40-1.55 (3H, m), 1.43 (9H, s), 1.33-1.43 (2H, m), 1.33 (6H, s).

(CI MS)  $M + 1 = 555$ .

Step (c) Preparation of: (S)-[5-(2,2,5,7,8-Pentamethyl-chroman-6-sulfonylamino)-1-(thiazole-2-carbonyl)-pentyl]-carbamic acid tert-butyl ester




To thiazole (0.3 mL, 4.2 mmol) and TMEDA (0.55 mL, 3.6 mmol) in THF (12.5 mL) at  $-78^\circ\text{C}$  was added  $n\text{BuLi}$  in hexane (1.8 mL, 1.94 M, 3.5 mmol). Raised temperature to  $-41^\circ\text{C}$ , stirred for 25 minutes, cooled to at  $-78^\circ\text{C}$ , added (12) (0.63 g, 1.14 mmol) in THF (6 mL). Stirred for 45 minutes. Quenched with saturated aqueous  $\text{NH}_4\text{Cl}$

(120 mL). Extracted with ethyl acetate (2 x 90 mL), dried with  $\text{MgSO}_4$ , filtered, removed solvent in vacuo. Purified with silica gel column eluted with 35% ethyl acetate in hexane to give 0.55 g (84%) of product (13).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 8.04 (1H, d,  $J = 3.13$ ), 7.71 (1H, d,  $J = 2.89$ ), 5.35-5.43 (2H, m), 4.45-4.55 (1H, m), 2.87 (2H, q), 2.65 (2H, t), 2.54 (3H, s), 2.53 (3H, s), 2.13 (3H, s), 1.90-2.00 (1H, m), 1.43-1.65 (6H, m), 1.43 (9H, s), 1.32 (6H, s).

(CI MS)  $M + 1 = 579$ .

Step (d) Preparation of: (S)-2,2,5,7,8-Pentamethyl-chroman-6-sulfonic acid (5-amino-6-oxo-6-thiazol-2-yl-hexyl)-amide



To (13) (0.47 g, 0.82 mmol) in dioxane (5 mL) was added ethyl methyl sulfide (0.5 mL, 5.5 mmol) and 4 M HCl in dioxane (5 mL). Stirred at room temperature for 1 hour. Added more 4 M HCl in dioxane (5 mL). Stirred for 15 minutes more. Removed solvent in vacuo. Triturated product with ethyl acetate (2 x 50 mL) and

-41-

diethyl ether (2 x 50 mL) to give 0.35 g of a yellow powder (14).


$^1\text{H}$  NMR ( $\text{d}_6\text{DMSO}$ , 400 MHz): 8.55 (2H, bs), 8.41 (1H, d,  $J = 3.04\text{Hz}$ ), 8.25 (1H, d,  $J = 2.89$ ), 7.23 (1H, t), 4.95-5.00 (1H, m), 2.70-2.80 (2H, m), 2.60 (2H, t), 2.41 (6H, s), 2.04 (3H, s), 1.81-1.97 (2H, m), 1.78 (2H, t), 1.30-1.41 (4H, m), 1.27 (6H, s).  
(CI MS)  $M + 1 = 480$ .

## EXAMPLE 5

(S)-N-[[[3-amino-4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-4-oxobutyl]aminoliminomethyl]-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide

Step (a) Preparation of: 2-Chloro-5,6-dihydro-4H-cyclopentathiazole

2-Amino-5,6-dihydro-4-cyclopentathiazole




15

To cupric chloride (2.65 g, 19.7 mmol) and tert butyl nitrite (3 mL, 24.6 mmol) in acetonitrile (65 mL) was added 2-amino-5,6-dihydro-4-cyclopentathiazole (2.3 g, 16.4 mmol, free amine prepared via methylene chloride extraction of a basic solution of corresponding HCl salt) over 15 minutes. Stirred at room temperature for 2 hours, then at 65°C for 1 hour. Filtered. Poured filtrate over 6N HCl (200 mL) and extracted with diethyl ether (300 mL). Dried with sodium sulfate, filtered, removed solvent in vacuo. Kugelrohr distilled on high vacuum pump at 95°C to give 1.0 g (38%) of product (15) as a clear oil.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 2.87-2.96 (2H, m), 2.80-2.85 (2H, m), 2.41-2.54 (2H, m).

(CI MS)  $M + 1 = 160$ .

Step (b) Preparation of: 5,6-dihydro-4H-cyclopentathiazole




10 To (15) (0.5 g, 3.1 mmol) in acetic acid (16.5 ml) at reflux was added zinc dust (0.48 g, 7.3 mmol). Refluxed for 3 hours. Poured over diethyl ether (120 mL) and saturated aqueous sodium bicarbonate (120 mL). Washed diethyl ether phase with brine (80 mL), dried with sodium sulfate, filtered, removed solvent to give 0.2 g (51%) of product (16).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 8.64 (1H, s), 2.86-2.94 (4H, m), 2.50-2.60 (2H, m).

(CI MS)  $M + 1 = 126$ ,  $M(\text{NH}_3) = 142$ .


Step (c) Preparation of: 1,1-dimethylethyl (S)-[1-[(2-benzothiazolyl)carbonyl]-4-[[imino[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]aminolmethyl]-aminolbutyl]carbamate



-43-

To (16) (0.63 g, 5.0 mmol) and TMEDA (0.7 mL, 4.7 mmol) in THF (10 mL) at  $-78^{\circ}\text{C}$  was added nBuLi in hexane (2.6 mL, 1.79 M, 4.6 mmol). Raised temperature to  $-41^{\circ}\text{C}$ , stirred for 25 minutes, cooled to at  $-78^{\circ}\text{C}$ , added (4) (Example 2, Step (a)) (0.65 g, 1.1 mmol) in THF (5 mL). Raised temperature to  $0^{\circ}\text{C}$ . Stirred for 90 minutes. Quenched with saturated aqueous  $\text{NH}_4\text{Cl}$  (120 mL). Extracted with ethyl acetate ( $2 \times 80$  mL), washed organic phase with brine (80 mL), dried with sodium sulfate, filtered, removed solvent in vacuo. Purified with silica gel column eluted with 75% ethyl acetate in hexane to give 0.52g (72%) of product (17).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz): 6.30 (1H, bs), 6.15 (2H, bs), 5.63 (1H, d,  $J = 7.47$  Hz), 5.38 (1H, t), 3.50-3.60 (1H, m), 3.20-3.30 (1H, m), 3.02 (2H, t), 2.89-2.98 (2H, m), 2.63 (2H, t), 2.57 (3H, s), 2.56 (3H, s), 2.52-2.55 (2H, m), 2.10 (3H, s), 1.80 (2H, t), 1.55-1.80 (4H, m), 1.42 (9H, s), 1.30 (6H, s). (CI MS)  $M + 1 = 648$ .

Step (d) Preparation of: (S)-N-[[[3-amino-4-(5,6-dihydro-4H-cyclopentathiazol-2-yl)-4-oxobutyl]aminoliminomethyl]-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide



17

18

To (17) (0.44 g, 0.68 mmol) in dioxane (2 mL) was added ethyl methyl sulfide (0.4 mL, 4.4 mmol) and 4 M HCl in dioxane (3 mL). Stirred at room temperature for 40 minutes. Removed solvent in vacuo. Triturated with ethyl acetate (3 x 50 mL) to give 0.43 g of a yellow-brown powder (18).


<sup>1</sup>H NMR (d<sub>6</sub>DMSO, 400 MHz): 8.57 (2H, bs), 6.98 (1H, bs), 6.49 (1H, bs), 5.19 (3H, bs), 4.92-4.94 (1H, m), 3.01-3.10 (4H, m), 2.88 (2H, t), 2.57 (2H, t), 2.43 (6H, s), 2.02 (3H, s), 1.83-2.00 (2H, m), 1.76 (2H, t), 1.37-1.56 (2H, m), 1.26 (6H, s).

(APCI MS) M + 1 = 548.7.

#### EXAMPLE 6

(S)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]aminoliminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide monohydrochloride

Step (a) Preparation of: 1,1-dimethylethyl (S)-[4-[[[imino[[[4-methoxy-2,3,6-trimethylphenyl]-sulfonyl]aminol]methyl]aminol]-1-[(1-methyl-1H-imidazol-2-yl)carbonyl]butyl]carbamate



1

19


-45-

To N-methylimidazole (1.38 mL, 17.4 mmol) in THF (40 mL) at -78°C was added n-BuLi in hexane (9.9 mL, 15.46 mmol, 1.56 M) titrated as described in J. Org. Chem., 509 (1989) at a rate that raised the internal temperature to -50°C. The reaction flask was placed in a dry ice/acetonitrile bath to give an internal temperature of -45°C. The reaction mixture stirred for 55 minutes, then cooled to -78°C. N,O-dimethylamide (1) (2.0 g, 3.77 mmol) in THF (20 mL) was added to the reaction mixture. The internal temperature rose to -55°C during the addition of (1) (Example 1, Step (a)). Once the addition was complete the reaction mixture was stirred for 1 hour. It was then poured over a saturated ammonium chloride solution and shook vigorously. The reaction mixture was extracted with ethyl acetate several times and the combined organic phases were washed with brine, dried with sodium sulfate, filtered, and the solvent was removed in vacuo. The product was purified on a silica gel column eluted with 2% ethanol/ethyl acetate to yield 0.98 g (49%) of the desired product (19).

NMR (DMSO-d<sub>6</sub>): 7.47 (1H, s), 7.09 (1H, s), 7.04 (1H, d, J = 8.03 Hz), 6.60 (1H, s), 6.30 (2H, m), 5.05 (1H, m), 3.83 (3H, s), 3.72 (3H, s), 2.94 (2H, m), 2.5 (3H, s), 2.4 (3H, s), 1.97 (3H, s), 1.38 (4H, m), 1.29 (9H, s).

(APCI MS) M + 1 = 551.5.

Step (b) Preparation of: (S)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]-aminoliminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide monohydrochloride



To (19) (0.46 g, 0.835 mmol) in dioxane (13 mL) was added ethyl methyl sulfide (0.35 mL) then 4 M HCl in dioxane (3 mL). The reaction mixture stirred at room temperature 1 hour and 15 minutes. The supernatant was decanted and the residue triturated with ethyl acetate, filtered, and rinsed thoroughly to yield 0.49 g of the desired product (20).

NMR (DMSO- $d_6$ ,  $D_2O$ ): 7.54 (1H, s), 7.16 (1H, s), 6.59 (1H, s), 4.82 (1H, t), 3.86 (3H, s), 3.70 (3H, s), 2.99 (2H, m), 2.47 (3H, s), 2.37 (3H, s), 1.95 (3H, s), 1.78 (2H, m), 1.37 (2H, m).


(ES MS)  $M + 1 = 451.5$ .

#### EXAMPLE 7

[S-(R\*,R\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide hydrochloride



Step (a) Preparation of: (S)-[1-(Methoxy-methyl-carbamoyl)-2-pyridin-3-yl-ethyl]-carbamic acid tert-butyl ester




To BOC-NH-3-pyridylalanine (10.5 g, 39.5 mmol) in methylene chloride (106 mL) was added BOP reagent (18.3 g, 41.48 mmol) and DIEA (7.56 mL, 43.45 mmol). The reaction mixture stirred at room temperature for 20 minutes. To the reaction mixture was added N,O-dimethylhydroxylamine hydrochloride (3.85 g, 39.5 mmol) followed by DIEA (7.56 mL). The reaction mixture stirred 4 hours and the solvents removed in vacuo. The residue was dissolved in ethyl acetate and washed with 1N NaOH (3 x 25 mL), water (2 x 25 mL) and brine (1 x 50 mL), dried over sodium sulfate, filtered, and the solvents removed in vacuo. The product was crystallized from ethyl acetate/hexane to yield 5.67 g of product. The filtrate was chromatographed on silica gel eluted with 80% ethyl acetate/hexane to 100% ethyl acetate to yield 4.4 g of product. Total yield 10.07 g (82%) of the desired product (21).

$^1\text{H}$  NMR (DMSO- $d_6$ ): 8.37 (2H, m), 7.59 (1H, d,  $J = 7.81$  Hz), 7.24 (2H, m), 4.49 (1H, m), 3.68 (3H, s), 3.05 (3H, s), 2.82 (1H, JAB = 13.67 Hz, JAX = 4.15 Hz), 2.68 (1H, JAB = 13.67 Hz, JBX = 10.36 Hz), 1.23 (9H, s).

(APCI MS)  $M + 1 = 310.5$ .

Step (b) Preparation of: [1-(Methoxy-methyl-carbamoyl)-2-piperidin-3-yl-ethyl]-carbamic acid tert-butyl ester




To (21) (4.4 g, 14.2 mmol) in acetic acid (100 mL) was added  $\text{PtO}_2$  (0.44 g) and hydrogen gas in a Parr reactor. The reaction was complete in 23 hours. The catalyst was filtered, and the reaction mixture concentrated in vacuo. The product was dissolved in water and lyophilized to yield 5.9 g of the desired product as a sticky oil (22).

$^1\text{H}$  NMR (DMSO): 7.05-7.02 (1H, d), 5.2 (1H, br), 4.36-4.30 (1H, m), 3.67 (3H, s), 3.03 (3H, s), 2.93 (3H, m), 2.50 (1H, m), 2.29 (1H, m), 1.61 (3H, m), 1.32 (2H, m), 1.31 (9H, s), 1.0 (1H, m).

(APCI MS)  $M + 1 = 316$ .

Step (c) Preparation of: [2-(1-carbamimidovl-piperidin-3-yl)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester




To (22) (6.75 g, 17.9 mmol) in DMF (9 mL) was added 1H-pyrazole-1-carboxamidine hydrochloride (2.6 g,

-49-

17.9 mmol) followed by DIEA (6.25 mL, 35 mmol). The reaction mixture stirred 4 hours at room temperature and the solvents removed in vacuo. The product was triturated with diethyl ether several times and the diethyl ether layer decanted. The product (23) was not purified but used as is in the subsequent reaction. (APCI MS)  $M + 1 = 358.6$ .

Step (d) Preparation of: [S-(R\*,S\*)]-[2-{1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl-amino)-methyl]-piperidin-3-yl}-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester (24-R) and [S-(R\*,R\*)]-[2-{1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-methyl]-piperidin-3-yl}-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester (24-S)



To (23) (0.56 g, 1.56 mmol) in acetone (6.8 mL) at 0°C was added 4N NaOH (1.7 mL) and 4-methoxy-2,3,6-trimethylbenzenesulfonyl chloride (0.679 g, 2.73 mmol) in acetone (1.7 mL). The reaction mixture stirred at 0°C for 2.5 hours. Added 10% citric acid until the pH = 6.0. The solvents were removed in vacuo. The residue was extracted with ethyl acetate


several times and the combined organic phases were washed with brine, dried over magnesium sulfate, filtered, and the solvents removed in vacuo. The product was purified on silica gel eluted with ethyl acetate to yield 396 mg (24-R) and 211 mg (24-S).

(24-R)  $^1\text{H}$  NMR ( $\text{DMSO}-d_6, \text{D}_2\text{O}$ ): 6.60 (1H, s), 4.31 (1H, m), 3.97 (1H, m), 3.98 (1H, m), 3.78 (1H, m), 3.70 (3H, s), 3.59 (3H, s), 2.99 (3H, s), 2.70 (1H, m), 2.50 (3H, s), 2.44 (3H, s), 2.42 (1H, m), 1.97 (3H, s), 1.62 (1H, m), 1.53 (1H, m), 1.28 (9H, s), 1.38-1.21 (2H, m), 1.20-1.0 (2H, m).

(24-S)  $^1\text{H}$  NMR ( $\text{DMSO}-d_6, \text{D}_2\text{O}$ ): 6.90 (1H, d), 6.62 (1H, s), 4.35 (1H, m), 3.71 (3H, s), 3.67 (2H, m), 3.60 (3H, s), 3.00 (3H, s), 2.83 (1H, m), 2.63 (1H, m), 2.50 (3H, s), 2.43 (3H, s), 1.98 (3H, s), 1.70 (1H, m), 1.55 (1H, m), 1.29 (9H, s), 1.45-1.0 (5H, m).

(APCI MS)  $M + 1 = 570.5$ .

Step (e) Preparation of: [S-(R\*,R\*)]-(1-(1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)amino]-methyl)-piperidin-3-ylmethyl)-2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid tert-butyl ester




To thiazole (0.26 g, 2.66 mmol) and TMEDA (0.37 mL, 2.44 mmol) in THF (6.3 mL) at -78°C was added n-BuLi in hexane (1.7 mL, 2.38 mmol, 1.4 M) at a rate that raised the internal temperature to -55°C. The reaction mixture was placed in a dry ice/acetonitrile bath to give an internal temperature of -41°C. Stirred for 25 minutes then cooled to -78°C. (24-S) (0.330 g, 0.58 mmol) in THF (3.2 mL) was added to the reaction mixture and stirred for 45 minutes. The reaction mixture was poured over saturated ammonium chloride solution, shook vigorously, and extracted several times with ethyl acetate. The combined organic phases were washed with brine and dried over sodium sulfate, filtered, and the solvent removed in vacuo. The product was purified on silica gel eluted with 70% ethyl acetate/hexanes to 100% ethyl acetate. Isolated 0.25 g (73%) of the desired product (25).

$^1\text{H}$  NMR (DMSO- $d_6$ ): 8.21 (1H, d,  $J = 2.93$  Hz), 8.12 (1H, d,  $J = 3.17$  Hz), 7.35 (1H, d,  $J = 7.57$  Hz), 6.94 (2H, s), 6.60 (1H, s), 5.36 (1H, m), 3.76 (2H, m), 3.73 (3H, s), 2.83 (1H, m), 2.63 (1H, m), 2.50 (3H, s), 2.43 (3H, s), 1.97 (3H, s), 1.81 (1H, m), 1.60 (2H, m), 1.20-1.18 (4H, m), 1.27 (9H, s).

(APCI MS)  $M + 1 = 594.4$ .

Step (f) Preparation of: [S-(R\*,R\*)]-N-[[3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide hydrochloride




To (25) (0.23 g, 0.39 mmol) in dioxane (1.2 mL) was added ethyl methyl sulfide (0.18 mL) then 4 M HCl in dioxane (1.56 mL). The reaction mixture stirred at room temperature for 40 minutes. A yellow gummy precipitate formed. The supernatant was decanted and the residue triturated with ethyl acetate to yield a yellow solid. Isolate the precipitate by filtration and wash with ethyl acetate to yield 0.267 g of the desired product (26).

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\text{D}_2\text{O}$ ): 8.24 (1H, d,  $J = 2.93$  Hz), 8.14 (1H, d,  $J = 2.93$  Hz), 6.59 (1H, s), 4.96 (1H, m), 3.8 (2H, m), 3.49 (3H, s), 2.85 (1H, m), 2.62 (1H, m), 2.47 (3H, s), 2.40 (3H, s), 1.99 (3H, s), 1.78 (1H, m), 1.60 (2H, m), 1.22 (4H, m).  
(ES MS)  $M + 1 = 494.5$ .

## EXAMPLE 8

[S-(R\*,S\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide hydrochloride

Step (a) Preparation of: [S-(R\*,S\*)]-(1-[1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonylami-  
no)-methyl]-piperidin-3-ylmethyl]-2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid  
tert-butyl ester



To thiazole (0.43 g, 5.0 mmol) and TMEDA (0.7 mL, 4.66 mmol) in THF (12 mL) at  $-78^{\circ}\text{C}$  was added n-BuLi in hexane (2.39 mL, 4.55 mmol, 1.9 M). The reaction mixture was placed in a dry ice/acetonitrile bath to give an internal temperature of  $-41^{\circ}\text{C}$ . Stirred for 20 minutes then cooled to  $-78^{\circ}\text{C}$ . (24-R) (Example 7, Step (d)) (0.63 g, 1.11 mmol) in THF (11 mL) was added to the reaction mixture at a rate that maintained an internal temperature of  $-78^{\circ}\text{C}$  and stirred for 50 minutes. The reaction mixture was poured over saturated ammonium chloride solution, shook vigorously, and extracted several times with ethyl acetate. The combined organic phases were washed with brine and


dried over sodium sulfate, filtered, and the solvent removed in vacuo. The product was purified on silica gel and eluted with 70% ethyl acetate/hexanes.

Isolated 0.56 g (85%) of the desired product (27).

<sup>1</sup>H NMR (DMSO): 8.21 (1H, d, J = 2.93 Hz), 8.12 (1H, d, J = 2.93 Hz), 7.52 (1H, d, J = 7.08 Hz), 6.98 (2H, s), 6.62 (1H, s), 5.13 (1H, m), 4.16 (1H, m), 3.84 (1H, m), 3.74 (3H, s), 2.72 (1H, m), 2.53 (3H, s), 2.46 (3H, s), 1.99 (3H, s), 1.68 (1H, m), 1.49 (4H, m), 1.30 (9H, s), 1.22-1.01 (2H, m).

(APCI MS) M + 1 = 594.

Step (b) Preparation of: [S-(R\*,S\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide hydrochloride



To (27) (0.50 g, 0.84 mmol) in dioxane (2.5 mL) was added ethyl methyl sulfide (0.35 mL) then 4 M HCl in dioxane (3.0 mL). The reaction mixture stirred at room temperature for 30 minutes. A yellow gummy precipitate formed. The supernatant was decanted and the residue triturated with ethyl acetate to yield a yellow solid. Isolate the precipitate by filtration



-55-

and wash with ethyl acetate to yield 0.57 g of the desired product (28).


<sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 8.57 (NH), 8.5 (NH), 8.44 (1H, d, J = 2.93 Hz), 8.20 (1H, d, J = 2.93 Hz), 7.08 (2H, NH), 6.64 (1H, s), 5.08 (1H, m), 3.93 (br, m), 3.74 (3H, s), 2.72 (1H, m), 2.63 (1H, m), 2.54 (3H, s), 1.99 (3H, s), 1.9-1.5 (5H, m), 1.2-1.0 (2H, m).

(ES MS) M + 1 = 494.

#### EXAMPLE 9

(S)-N-[[4-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide

Step (a) Preparation of: (S)-(1-{1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-methyl]-piperidin-4-ylmethyl}-2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid tert-butyl ester



To thiazole (0.38 mL, 5.37 mmol) and TMEDA (0.75 mL, 14.9 mmol) in THF (12.9 mL) at -78°C was

added n-BuLi in hexane (2.6 mL, 4.87 mmol, 1.87 M) at a rate that raised the internal temperature to -45°C.

The flask was placed in a dry ice/acetonitrile bath to give an internal temperature of -45°C. The reaction

5 mixture was stirred for 30 minutes and then cooled to

-78°C. The N,O-dimethylamide, (S)-[2-{1-[Imino-  
(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-

methyl]-piperidin-4-yl}-1-(methoxy-methyl-carbamoyl)-  
ethyl]-carbamic acid tert-butyl ester prepared in a

10 similar manner to Example 7 Steps (a)-(d), (0.68 g,

1.19 mmol) in THF (10 mL) was added. The reaction

mixture was stirred 50 minutes then poured into  
saturated ammonium chloride solution, shook vigorously,

and extracted several times with ethyl acetate. The

15 combined organics were washed with brine, dried over

sodium sulfate, filtered, and the solvent removed

in vacuo. The product was purified on silica gel


column eluted with 80% ethyl acetate/20% hexane to

yield 0.72 g of the desired product (29).

20 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): 8.21 (1H, d, J = 2.93 Hz), 8.13 (1H,  
d, J = 2.93 Hz), 7.36 (1H, d, J = 7.57 Hz), 6.97 (2H,  
brs), 6.63 (1H, s), 5.14 (1H, m), 3.97 (2H, m), 3.73  
(3H, s), 2.71 (2H, m), 2.53 (3H, s), 2.45 (3H, s), 1.99  
(3H, s), 1.8-1.4 (5H, m), 1.30 (9H, s), 1.09 (1H,m),  
25 0.94 (1H, m).

(APCI MS) M + 1 = 594.5.

Step (b) Preparation of: (S)-N-([4-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide



To (29) (0.49 g, 0.83 mmol) in dioxane (1.5 mL) was added ethyl methyl sulfide (0.35 mL) then 4 M HCl in dioxane (3.0 mL). The reaction mixture stirred at room temperature for 45 minutes and a gummy precipitate formed. The supernatant was decanted and ethyl acetate (15 mL) was added to the residue and stirred until a fine granular precipitate formed. The product was isolated by filtration and washed thoroughly with ethyl acetate to yield 0.517 g (98%) of the desired product (30).

$^1\text{H}$  NMR (DMSO): 8.43 (3H, br s), 8.35 (1H, d,  $J = 2.93$  Hz), 8.21 (1H, d,  $J = 2.93$  Hz), 7.00 (2H, br s), 6.62 (1H, s), 5.01 (1H, m), 3.82 (2H, m), 3.73 (3H, s), 2.80 (1H, m), 2.57 (1H, m), 2.52 (3H, s), 2.45 (3H, s), 1.98 (3H, s), 1.80 (1H, m), 1.50 (2H, m), 1.30 (2H, m), 1.16 (2H, m).


(APCI MS)  $M + 1 = 494.2$ .

-58-

## EXAMPLE 10

(S)-N-[[[4-amino-5-(2-benzisothiazolyl)-5-oxopentyl]-aminoliminomethyl]-4-methoxy-2,3,6-trimethylbenzene-sulfonamide monohydrochloride

Step (a) Preparation of: 1,1-dimethylethyl (S)-[1-[(2-benzisothiazolyl)carbonyl]-4-[[imino[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-aminolmethyl]aminolbutyl]carbamate




To benzothiazole (0.94 mL, 8.6 mmol) and TMEDA (1.19 mL, 7.9 mmol) in THF (20 mL) at -78°C was added n-BuLi in hexane (3.85 mL, 7.7 mmol, 2.0 M) at a rate that raised the internal temperature to -60°C. The reaction mixture stirred for 40 minutes at -60°C to -78°C. Added (1) (Example 1, Step (a)) (1.0 g, 1.88 mmol) in THF (10 mL) and stirred for 45 minutes [Note: internal temperature rises to -60°C during the addition of (1)]. The reaction mixture was poured over saturated ammonium chloride solution and extracted several times with ethyl acetate. The combined organics were washed with brine, dried over sodium sulfate, filtered, and the solvent was removed

in vacuo. The product was purified on silica gel column eluted with 70% ethyl acetate/hexanes to yield 560 mg of the desired product (31).

$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ): 8.19 (2H, m), 7.61 (2H, m), 7.46 (1H, d,  $J = 7.08$  Hz), 6.58 (1H, s), 5.14 (1H, m), 3.72 (3H, s), 3.0 (3H, m), 2.45 (3H, s), 2.44 (3H, s), 1.94 (3H, s), 1.82 (1H, m), 1.52 (3H, m), 1.30 (9H, s).

(APCI MS)  $M + 1 = 604.4$ .

Step (b) Preparation of: (S)-N-[[[4-amino-5-(2-benz-isothiazolyl)-5-oxopentyl]aminoliminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide monohydrochloride



To (31) (0.56 g, 0.93 mmol) in dioxane (2.75 mL) was added ethyl methyl sulfide (0.38 mL) then 4 M HCl in dioxane (3.3 mL). Stirred at room temperature for 1 hour and a yellow gummy precipitate formed. The supernatant was decanted and the residue triturated with ethyl acetate. The precipitate was isolated by filtration and washed thoroughly with ethyl acetate to yield 348 mg of the desired product (32).

-60-


$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ): 8.47 (NH, s), 8.27 (2H, m), 8.23 (2H, m), 7.66 (NH, m), 6.57 (1H, s), 5.11 (1H, m), 3.72 (3H, s), 3.0 (2H, m), 2.45 (3H, s), 2.4 (3H, s), 1.93 (3H, s), 2.08-1.8 (2H, m), 1.58-1.40 (2H, m).

(APCI MS)  $M + 1 = 504.4$ .

# EXAMPLE 11

(S)-N-[[[4-amino-5-(2-pyridinyl)-5-oxopentylaminol-  
iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfon-  
amide monohydrochloride

Step (a) Preparation of: 1,1-dimethylethyl (S)-[4-  
[[imino[[[4-methoxy-2,3,6-trimethylphenyl)sul-  
fonylaminolmethyl]aminol]-1-[(2-pyridinyl)-  
carbonyl]butyl]carbamate




To 2-bromopyridine (0.82 mL, 8.66 mmol) in THF (10 mL) at  $-78^\circ\text{C}$  was added  $n\text{-BuLi}$  in hexane (5.5 mL, 7.94 mmol, 1.54 M), at a rate that kept the internal temperature at  $-78^\circ\text{C}$ . The reaction mixture was stirred at  $-78^\circ\text{C}$  for 30 minutes. The  $N,O$ -dimethylamide (1) (Example 1, Step (a)) (1.0 g, 1.89 mmol) in THF (5 mL) was added to the reaction mixture and stirred for 1 hour. The reaction mixture was poured over saturated

ammonium chloride solution, shook vigorously, and extracted several times with ethyl acetate. The combined organic phases were washed with brine, dried with sodium sulfate, filtered, and the solvent removed in vacuo. The product was purified on a silica gel column eluted with ethyl acetate to yield 0.62 g (63%) of the desired product (**33**).

$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ): 7.88 (1H, d), 7.63 (1H, m), 7.14 (1H, d,  $J = 7.81$  Hz), 6.80 (1H, br), 6.60 (1H, s), 6.30 (1H, br), 5.30 (1H, m), 3.73 (3H, s), 2.97 (2H, m), 2.51 (3H, s), 2.42 (3H, s), 1.97 (3H, s), 1.62 (1H, br), 1.40 (1H, br), 1.29 (9H, s), 0.83 (1H, s).  
(CI MS)  $M + 1 = 548$ .

Step (b) Preparation of: (S)-N-[[[4-amino-5-(2-pyridinyl)-5-oxopentyl]aminol-iminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide monohydrochloride



To (**33**) (0.3 g, 0.55 mmol) in dioxane (1.0 mL) was added ethyl methyl sulfide (0.23 mL) then 4 M HCl in dioxane (2.0 mL). Stirred at room temperature for 30 minutes. The product that precipitated was

-62-

filtered, and washed thoroughly with ethyl acetate to yield 0.27 g (98%) of the desired product (34).


$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ): 8.71 (1H, d,  $J = 4.15$  Hz), 8.39 (3H, br s), 8.02 (2H, m), 7.72 (1H, m), 6.61 (1H, s), 5.16 (1H, m), 3.73 (3H, s), 2.97 (2H, m), 2.50 (3H), 2.40 (3H, s), 1.98 (3H, s), 1.88 (1H, m), 1.7 (1H, m), 1.4 (2H, m).

(CI MS)  $M + 1 = 448$ .

## EXAMPLE 12

(S)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-2-yl)-5-oxopentyl]aminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide monohydrochloride

Step (a) Preparation of: 1,1-dimethylethyl (S)-[[[imino[[[4-methoxy-2,3,6-trimethylphenyl]-sulfonyl]aminomethyl]aminol-1-[(1-methyl-1H-benzimidazol-2-yl)carbonyl]butyl]carbamate



To 2-methylbenzoimidazole (2.29 g, 17.3 mmol) in THF (30 mL) at  $-78^{\circ}\text{C}$  was added  $n\text{-BuLi}$  in hexane (10.2 mL, 15.8 mmol, 1.54 M). The reaction mixture stirred for 45 minutes, then added N,O-dimethyl amide (1) (Example 1, Step (a)) (2.0 g, 3.78 mmol) in THF




(20 mL) while maintaining an internal temperature of  $-78^{\circ}\text{C}$ . The reaction mixture was stirred 2 hours. The reaction mixture was poured over saturated ammonium chloride solution (200 mL), shook vigorously, and then extracted with ethyl acetate. The combined organic phases were washed with brine and dried with sodium sulfate, filtered, and the solvent removed in vacuo. The product was purified on a silica gel column eluted with 80% ethyl acetate/hexane to yield 0.78 g (34%) of the desired product (35).

$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ): 7.79 (1H, d,  $J = 8.05$  Hz), 7.68 (1H, d,  $J = 8.3$  Hz), 7.31 (2H, m), 7.313 (1H, t,  $J_1 = 8.3$  Hz,  $J_2 = 7.08$  Hz), 7.29 (1H, s), 6.9 (1H, br), 6.59 (1H, s), 6.31 (1H, br), 5.24 (1H, m), 4.02 (3H, s), 3.72 (3H, s), 2.98 (2H, m), 2.50 (3H, s), 2.41 (3H, s), 1.95 (3H, s), 1.75 (2H, m), 1.48 (2H, m), 1.29 (9H, s).

(CI MS)  $M + 1 = 601$ .

Step (b) Preparation of: (S)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-2-yl)-5-oxopentyl]aminoliminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide monohydrochloride



To (35) (0.24 g, 0.4 mmol) in dioxane (1.0 mL) was added ethyl methyl sulfide (0.23 mL) then 4 M HCl in dioxane (2.0 mL). The reaction mixture stirred 1 hour at room temperature. A white precipitate formed and the supernatant was decanted and ethyl acetate (45 mL) was added to the residue. The product was stirred until it became a granular precipitate. The product was isolated by filtration and washed thoroughly with ethyl acetate to yield 0.19 g (98%) of the desired product (36).

<sup>1</sup> NMR (DMSO-d<sub>6</sub>): 8.47 (2H, br), 7.82 (1H, d, J = 8.05 Hz), 7.75 (1H, d, J = 8.54 Hz), 7.49 (1H, t, J1 = 7.32 Hz, J2 = 7.08 Hz), 7.37 (1H, t, J1 = 8.05 Hz, J2 = 7.32 Hz), 6.90 (1H, br), 6.58 (1H, s), 6.40 (1H, br), 5.12 (1H, m), 4.07 (3H, s), 3.71 (3H, s), 2.98 (2H, m), 2.45 (3H, s), 2.37 (3H, s), 1.96 (1H, m), 1.93 (3H, s), 1.84 (1H, m), 1.44 (2H, m).

(APCI MS) M + 1 = 501.

#### EXAMPLE A

[6S-[6a[R\*(R\*)].8a]]-2-(3-Phenyl-propionyl)-octahydro-pyrrolo[1,2-*a*pyrazine-6-carboxylic acid[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-amide trifluoroacetate

To a solution of 4-oxo-2-(3-phenyl-propionyl)-octahydro-pyrrolo[1,2-*a*pyrazine-6-carboxylic acid (0.155 g, 0.490 mmol) (HPLC retention time 7.23 minutes, eluting with a gradient of 20% acetonitrile to 76% acetonitrile in water containing 0.1% TFA over 22 minutes) in DMF (3 mL) at room temperature was added the (3) (Example 1, Step (c)) (0.309 g, 1.2 equiv.), diisopropylethylamine (0.42 mL, 4 equiv.) and then BOP-reagent (0.326 g, 1.5 equiv.). The mixture was stirred for 3 hours and then diluted with water (50 mL) and extracted with ethyl acetate (2 × 50 mL). The organic phase was washed with brine (50 mL), dried over MgSO<sub>4</sub> and then purified by silica

gel chromatography, eluting with 95% ethylacetate/5% methanol, to afford the intermediate [6S-[6 $\alpha$ R\*(R\*), 8 $\alpha$ ]]-[4-[[imino[[4-methoxy-2,3,6-trimethylphenyl)-sulfonyl]amino]methyl]amino]-1-[(2-thiazolyl)carbonyl]-butyl]octahydro-4-oxo-2-(1-oxo-3-phenylpropyl)pyrrolo-[1,2-a]pyrazine-6-carboxamide (0.260 g, 71%). To a solution of this compound (0.260 g, 0.346 mmol) in thioanisole (0.3 mL) at room temperature was added TFA (3 mL). This solution was stirred at room temperature for 2.5 hours and then evaporated in vacuo and treated with diethyl ether to precipitate a white solid. This solid was purified by reverse phase chromatography eluting with 80% acetonitrile in 20% water containing 0.1% TFA. The appropriate fractions were combined and lyophilized to afford the title compound (A) (0.102 g, 45%).

<sup>1</sup> NMR (DMSO-d<sub>6</sub>): 8.84 (1H, d, J = 7.0 Hz), 8.28 (1H, d, J = 3.1 Hz), 8.19 (d, J = 2.9 Hz), 7.45 (1H, t, J = 5.5 Hz), 7.25 (5H, m), 7.17 (1H, m), 5.36 (1H, m), 4.62 (1H, m), 4.45 (2H, m), 4.25 (2H, m), 3.81 (1H, d, J = 17 Hz), 3.65-3.50 (1H, m), 3.47 (1H, d, J = 17 Hz), 3.1 (2H, m), 2.95 (1H, m), 2.90 (2H, m), 2.85 (1H, m), 2.6-2.4 (2H, m), 2.35-2.18 (1H, m), 2.05 (1H, m), 1.95 (1H, m), 1.65 (4H, m), 1.45 (1H, m).  
(ES MS) 540.

#### EXAMPLE B

[6S-[6 $\alpha$ [R\*(R\*)], 8 $\alpha$ ]]-2-(3-Phenyl-propionyl)-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid[1-(1-carbamimidoyl-piperidin-3-ylmethyl)-2-oxo-2-thiazol-2-yl-ethyl]-amide trifluoroacetate

To (26) (Example 1, Step (f)) (0.225 g, 0.42 mmol) and 4-oxo-2-(3-phenyl-propionyl)-octahydro-pyrrolo-[1,2-a]pyrazine-6-carboxylic acid (0.124 g, 0.39 mmol) (HPLC retention time 7.23 minutes, eluting with a gradient of 20% acetonitrile to 76% acetonitrile in

-66-


water containing 0.1% TFA over 22 minutes) in DMF (3.9 mL) was added BOP reagent (0.263 g, 0.595 mmol) and N-methyl morpholine (0.22 mL, 2.0 mmol). The reaction mixture was stirred at room temperature for 3.5 hours. The reaction mixture was diluted with ethyl acetate and washed with 10% citric acid, then brine, dried with sodium sulfate, filtered, and the solvent removed in vacuo. The product was purified on a silica gel column eluted with 5% methanol/ethyl acetate. Isolated 0.127 g (42%) of the desired product [6S-[6 $\alpha$ [R\*(R\*)],8 $\alpha$ ]]-N-[1-[[1-[imino[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino)methyl]-3-piperidinyl)methyl]-oxo-2-(2-thiazolyl)ethyl]-octahydro-4-oxo-2-(1-oxo-3-phenylpropyl)pyrrolo-[1,2-a]pyrazine-6-carboxamide. To this compound (0.113 g, 0.142 mmol) and ethyl methyl sulfide (0.12 mL) at 0°C was added TFA (1.1 mL). The reaction mixture stirred at 0°C for 30 minutes and at room temperature for 6 hours. To the mixture was added TFA (1.0 mL) and the reaction stirred an additional 30 minutes. The TFA and ethyl methyl sulfide were removed in vacuo and the residue triturated with diethyl ether. The precipitate was isolated by filtration and washed thoroughly with diethyl ether. The product was purified by reverse phase high pressure liquid chromatography eluting with acetonitrile/water, containing 0.1% TFA, to yield 42.9 mg of the desired product (B).

NMR (DMSO-d<sub>6</sub>): 8.63 (1H, d, J = 7.23 Hz), 8.48 (1H, d, J = 3.13 Hz), 8.19 (1H, d, J = 3.13 Hz), 7.25 (8H, m), 5.45 (1H, m), 4.70 (1H, m), 4.42 (2H, m), 4.24 (1H, m), 2.98 (2H, m), 2.83-2.68 (6H, m), 2.62-2.53 (1H, m), 2.19 (1H, m), 2.02 (1H, m), 1.90 (1H, m), 1.88-1.44 (7H, m), 1.25 (1H, m).

MS (ES) M + 1 = 580.

CLAIMS

1. A process for the preparation of a compound of Formula I(D(-)) or Formula I(L(+))



10 wherein R<sup>1</sup> is (CH<sub>2</sub>)<sub>n</sub>-R<sup>4</sup>

15 wherein X is O,

S, or

NR<sup>5</sup> wherein R<sup>5</sup> is H,

alkyl,

alkenyl,

alkynyl,

20 cycloalkyl,

cycloalkylalkyl,

aryl, or

arylalkyl,

25 n is zero or an integer of 1 to 4, and

R<sup>4</sup> is H,

halogen,

NHR<sup>5</sup> wherein R<sup>5</sup> is as defined

above,

30 NR<sup>5</sup>(R<sup>5a</sup>) wherein R<sup>5</sup> and R<sup>5a</sup> are the same or different and are as defined above for R<sup>5</sup>,

OR<sup>5</sup> wherein R<sup>5</sup> is as defined above,

NO<sub>2</sub>,

CN,

-68-

35

$\text{SO}_4\text{R}^5$  wherein  $\text{R}^5$  is as defined  
above,

$\text{C}(=\text{O})\text{NR}^5\text{R}^{5a}$  wherein  $\text{R}^5$  and  $\text{R}^{5a}$  are  
the same or different and are  
as defined above for  $\text{R}^5$ ,

40


$\text{CO}_2\text{R}^5$  wherein  $\text{R}^5$  is as defined  
above,

$\text{C}(=\text{O})\text{R}^5$  wherein  $\text{R}^5$  is as defined  
above,

45


aryl, or  
heteroaryl,

50




wherein  $t$  is zero or an  
integer of 1 to 3, and  $X$ ,  
 $n$ , and  $\text{R}^4$  are as defined  
above,

55




wherein  $X$ ,  $n$ , and  $\text{R}^4$  are as  
defined above,

60




wherein  $n$  and  $\text{R}^4$  are as  
defined above,

65




wherein  $n$  and  $\text{R}^4$  are as  
defined above,

70




wherein  $n$  and  $\text{R}^4$  are as  
defined above,



wherein n and R<sup>4</sup> are as defined above;

R<sup>2</sup> is -(CH<sub>2</sub>)<sub>q</sub>-Y wherein Y is



wherein R<sup>5</sup> is as defined above, and R<sup>6</sup>, R<sup>6a</sup>, R<sup>6b</sup>, R<sup>6c</sup>, R<sup>6d</sup> are the same or different and are H,


alkyl,

alkenyl,


alkynyl,

cycloalkyl, or

OR<sup>5</sup> wherein R<sup>5</sup> is as defined above,



wherein R<sup>5</sup>, R<sup>6</sup>, R<sup>6a</sup>, R<sup>6b</sup>, R<sup>6c</sup>, and R<sup>6d</sup> are as defined above,




-70-

wherein p is zero or an integer of 1 to 2,  
and R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6c</sup>, and R<sup>6d</sup> are as  
defined above, or


110

115




wherein p, R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6c</sup>, and R<sup>6d</sup> are as  
defined above, and q is an integer of  
3 to 6,

120




wherein u is zero or an  
integer of one, and  
p and Y are as defined  
above,

125




wherein u and Y are as defined  
above,

130



wherein Z is


135




140




wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ ,  
and  $R^{6d}$  are as defined  
above, or




wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ ,  
and  $R^{6d}$  are as defined  
above, and wherein  $u$  is  
as defined above,




wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above,




wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above,




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,



wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,



-72-


wherein  $u$ ,  $R^{5a}$ ,  $R^5$  and  $Y$  are  
as defined above,

180



wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above, or

185




wherein  $u$ ,  $R^{5a}$  and  $Y$  are as  
defined above; and

$R^3$  is H,

190

$-CO_2R^7$  wherein  $R^7$  is alkyl,  
cycloalkyl,  
cycloalkylalkyl,  
arylalkyl, or  
aryl, or,

195



wherein  $R^7$  is as defined above; or


an addition salt thereof;

which comprises:


200

step (a) treating a compound of Formula IIIa  
(D(-)) or Formula IIIa (L(+))

205



or




IIIa (D(-))

IIIa (L(+))


210

wherein  $R^{3a}$  is  $CO_2R^7$

wherein  $R^7$  is as defined above, or




215 and  $R^2$  is as defined above;  
with an activating agent in a solvent to afford an  
activated acyl intermediate which is treated with  
a compound of formula:



225 wherein  $R^8$  and  $R^{8a}$  may be the same or  
different and are

alkyl,  
cycloalkyl,  
cycloalkylalkyl, or

230  $R^8$  and  $R^{8a}$  may be joined to form a  
ring of from 4 to 8 atoms, to afford a  
compound of Formula IIa (D(-)) or  
Formula IIa (L(+))



wherein  $R^2$ ,  $R^{3a}$ ,  $R^8$ , and  $R^{8a}$  are as defined  
above;


245 step (b) treating a compound of Formula IIa  
(D(-)) or Formula IIa (L(+)) with a compound of  
Formula IV

-74-

 $R^1-M$ 


IV

wherein M is lithium, cerium halide, titanium  
alkoxide, titanium halide, or magnesium halide and  
250  $R^1$  is as defined above, in a solvent to afford a  
compound of Formula Ia (D(-)) or Formula Ia (L(+))



260 wherein  $R^1$ ,  $R^2$ , and  $R^{3a}$  are as defined above;

step (c) treating a compound of Formula Ia  
(D(-)) or Formula Ia (L(+)) with a deprotecting  
reagent in a solvent to afford a compound of  
265 Formula Ib (D(-)) or Formula Ib (L(+))



wherein  $R^1$  and  $R^2$  are as defined above.



2. A process according to Claim 1 wherein the  
activating reagent in step (a) is selected from  
the group consisting of: isobutylchloroformate,  
oxalyl chloride, thionyl chloride, diisopropyl  
carbodiimide, dicyclohexyl carbodiimide,  
5 1,1'-carbonyl-diimidazole, 2-chloro-1-methyl-  
pyridinium iodide, 2-ethoxy-1-ethoxycarbonyl-

-75-

1,2-dihydro-quinoline, benzotriazole-1-yl-oxy-  
tris-pyrrolidino-phosphonium hexafluorophosphate,  
10 bromo-tris-pyrrolidino-phosphonium hexafluoro-  
phosphate, 2-(1H-benzotriazole-1-yl)-  
1,1,3,3-tetramethyluronium tetrafluoroborate,  
1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide,  
and BOP-reagent.

3. A process according to Claim 2 wherein the  
activating reagent in step (a) is isobutylchloro-  
formate.
4. A process according to Claim 1 wherein the solvent  
in step (a) is selected from the group consisting  
of: ethyl acetate, chloroform, methylene  
chloride, dichloroethane, tetrahydrofuran,  
5 dimethylformamide, and dimethylsulfoxide.
5. A process according to Claim 4 wherein the solvent  
in step (a) is methylene chloride.
6. A process according to Claim 1 wherein M in a  
compound of Formula IV in step (b) is selected  
from the group consisting of: cerium halide,  
magnesium halide, titanium halide, titanium  
5 alkoxide, and lithium.
7. A process according to Claim 6 wherein M of  
Formula IV is lithium.
8. A process according to Claim 1 wherein the solvent  
in step (b) is selected from the group consisting  
of: tetrahydrofuran, dioxane, diisopropyl ether,  
and diethyl ether.

9. A process according to Claim 8 wherein the solvent is tetrahydrofuran.
10. A process according to Claim 1 wherein  $R^{3a}$  of Formula Ia (D(-)) or Formula Ia (L(+)) is tert-butoxycarbonyl and the deprotecting reagent in step (c) is selected from the group consisting of: trifluoroacetic acid and hydrogen chloride.
11. A process according to Claim 10 wherein the deprotecting reagent is hydrogen chloride.
12. A process according to Claim 1 wherein the solvent in step (c) is selected from the group consisting of: dioxane, ethyl acetate, methylene chloride, dichloroethane, and diethyl ether.
13. A process according to Claim 12 wherein the solvent is dioxane.
14. A compound of Formula I (D(-)) or Formula I (L(+))




wherein X is O,  
S, or  
 $\text{NR}^5$  wherein  $\text{R}^5$  is H,

-77-


alkyl,  
alkenyl,  
alkynyl,  
20 cycloalkyl,  
cycloalkylalkyl,  
aryl, or  
arylalkyl,  
n is zero or an integer of 1 to 4, and  
25  $R^4$  is H,  
halogen,  
NHR<sup>5</sup> wherein R<sup>5</sup> is as defined  
above,  
NR<sup>5</sup>(R<sup>5a</sup>) wherein R<sup>5</sup> and R<sup>5a</sup> are the  
30 same or different and are as  
defined above for R<sup>5</sup>,  
OR<sup>5</sup> wherein R<sup>5</sup> is as defined above,  
NO<sub>2</sub>,  
CN,  
35 SO<sub>4</sub>R<sup>5</sup> wherein R<sup>5</sup> is as defined  
above,  
C(=O)NR<sup>5</sup>R<sup>5a</sup>) wherein R<sup>5</sup> and R<sup>5a</sup> are  
the same or different and are  
as defined above for R<sup>5</sup>,  
40 CO<sub>2</sub>R<sup>5</sup> wherein R<sup>5</sup> is as defined  
above,  
C(=O)R<sup>5</sup> wherein R<sup>5</sup> is as defined  
above,  
aryl, or  
45 heteroaryl,

50




wherein  $t$  is zero or an integer of 1 to 3, and  $X$ ,  $n$ , and  $R^4$  are as defined above,

55




wherein  $X$ ,  $n$ , and  $R^4$  are as defined above,

60




wherein  $n$  and  $R^4$  are as defined above,

65




wherein  $n$  and  $R^4$  are as defined above,

70




wherein  $n$  and  $R^4$  are as defined above,

75




wherein  $n$  and  $R^4$  are as defined above,

80



wherein  $n$  and  $R^4$  are as defined above;

$R^2$  is  $-(CH_2)_q-Y$  wherein  $Y$  is



85



-79-

wherein  $R^5$  is as defined above, and  $R^6$ ,  $R^{6a}$ ,  
 $R^{6b}$ ,  $R^{6c}$ ,  $R^{6d}$  are the same or different  
 and are H,


alkyl,

alkenyl,


alkynyl,

cycloalkyl, or


OR<sup>5</sup> wherein  $R^5$  is as defined above,



wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as  
 defined above,




wherein  $p$  is zero or an integer of 1 to 2,  
 and  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as  
 defined above, or




wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, and  $q$  is an integer of 3 to 6,

125




wherein  $u$  is zero or an integer of one, and  $p$  and  $Y$  are as defined above,

130




wherein  $u$  and  $Y$  are as defined above,

135



wherein  $Z$  is


140



145

wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above, or

150




155

-81-


wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ ,  
and  $R^{6d}$  are as defined  
above, and wherein  $u$  is  
as defined above,

160




wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above,

165




wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above,

170




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,

175




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,




wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above,

180




wherein  $u$ ,  $R^{5a}$ ,  $R^5$  and  $Y$  are  
as defined above,

185



wherein  $u$ ,  $R^{5a}$ , and  $Y$  are as  
defined above, or

190



wherein  $u$ ,  $R^{5a}$  and  $Y$  are as  
defined above; and

$R^3$  is H,


$-CO_2R^7$  wherein  $R^7$  is alkyl,

cycloalkyl,

cycloalkylalkyl,

arylalkyl, or


aryl, or



wherein  $R^7$  is as defined above; or an

addition salt thereof.

15. A compound according to Claim 14 wherein



wherein X is O,

S, or

$NR^5$  wherein  $R^5$  is H,

alkyl,

alkenyl,


alkynyl,

cycloalkyl,


cycloalkylalkyl,

aryl, or


arylalkyl,



wherein X is as defined above,





wherein X is as defined above,




wherein X is as defined above,

-83-



$R^2$  is  $-(CH_2)_q-Y$  wherein  $Y$  is



wherein  $R^5$  is as defined above, and  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ ,  $R^{6d}$  are the same or different and are H,


alkyl,

alkenyl,


alkynyl,

cycloalkyl, or


$OR^5$  wherein  $R^5$  is as defined above,




wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ , and  $R^{6d}$  are as defined above,




wherein p is zero or an integer of 1 to 2,  
and R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6c</sup>, and R<sup>6d</sup> are as  
defined above, or




wherein p, R<sup>5</sup>, R<sup>5a</sup>, R<sup>6</sup>, R<sup>6c</sup>, and R<sup>6d</sup> are as  
defined above, and q is an integer of  
3 to 6,




wherein u is zero or an  
integer of one, and  
p and Y are as defined  
above,



wherein u and Y are as defined  
above,




wherein Z is




-85-


wherein  $R^5$ ,  $R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^{6c}$ ,  
and  $R^{6d}$  are as defined  
above, or



wherein  $p$ ,  $R^5$ ,  $R^{5a}$ ,  $R^6$ ,  $R^{6c}$ ,  
and  $R^{6d}$  are as defined  
above, and wherein  $u$  is  
as defined above,







wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above,




wherein  $u$ ,  $p$ , and  $Z$  are as  
defined above, and

$R^3$  is H or  $CO_2R^7$  wherein  $R^7$  is alkyl.

16. A compound according to Claim 15 wherein  $R^2$  is  $-(CH_2)_3-Y$  wherein Y is




25  $-(CH_2)_4-Y$  wherein Y is as defined above,






-87-


35



40



45




or


50

wherein u is as defined above,

55




60




$\text{R}^3$  is H, or

$-\text{CO}_2\text{R}^7$  wherein  $\text{R}^7$  is alkyl.

17. A compound of Formula I (D(-)) or Formula I (L(+)):




10 wherein R<sup>1</sup> is



15 wherein X is O,

S, or

NMe, or




wherein X is as defined above,


-89-

$R^2$  is  $-(CH_2)_3-Y$  wherein Y is


25



30




35




, or

40




45




50

wherein Y is as defined above,




wherein Y is as defined above,



55



wherein Z is




or



wherein Z is as defined above,


and  $R^3$  is  $CO_2t-Bu$ .

18. A compound of Formula I (D(-)) or Formula I (L(+)):




I (D(-))

or




I (L(+))

wherein  $R^1$  is






-91-

wherein X is O,  
S, or  
NMe, or





wherein X is as defined above,

$R^2$  is  $-(CH_2)_3-Y$  wherein Y is




, or




wherein Y is as defined above,

50




wherein Y is as defined above,

55




wherein Z is


60



65



70



wherein Z is as defined above, and  
R<sup>3</sup> is H; or an addition salt thereof.

19. A compound selected from the group consisting of:
- 1,1-dimethylethyl (S)-[4-[[imino[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-amino]-1-[(2-thiazolyl)carbonyl]butyl]carbamate;
  - 1,1-dimethylethyl (S)-[4-[[imino-[[3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]methyl]amino]-1-[(2-thiazolyl)carbonyl]butyl]carbamate;
  - 1,1-dimethylethyl (S)-[4-[[imino[[4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-amino]-1-[(1-methyl-1H-benzimidazol-2-yl)-carbonyl]butyl]carbamate;

1,1-dimethylethyl (S)-[4-[[imino-  
15 [[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzo-  
pyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(1-methyl-1H-benzimidazol-2-yl)carbonyl]butyl]-  
carbamate;

1,1-dimethylethyl (S)-[1-[(2-benzisothia-  
20 zolyl)carbonyl]-4-[[imino[[ (4-methoxy-2,3,6-tri-  
methylphenyl)sulfonyl]amino]methyl]amino]butyl]-  
carbamate;

1,1-dimethylethyl (S)-[1-[(2-benzisothia-  
25 zolyl)carbonyl]-4-[[imino[[ (3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)-  
sulfonyl]amino]methyl]amino]butyl]carbamate;

1,1-dimethylethyl (S)-[4-[[imino[[ (4-methoxy-  
2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-  
amino]-1-[(2-pyridinyl)carbonyl]butyl]carbamate;

1,1-dimethylethyl (S)-[4-[[imino-  
30 [[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-  
1-benzopyran-6-yl)sulfonyl]amino]methyl]amino]-  
1-[(2-pyridinyl)carbonyl]butyl]carbamate;

[S-(R\*,S\*)]-(1-{1-[Imino-(4-methoxy-  
2,3,6-trimethyl-benzenesulfonylamino)-methyl]-  
35 piperidin-3-ylmethyl)-2-oxo-2-thiazol-2-yl-ethyl)-  
carbamic acid tert-butyl ester;

[S-(R\*,S\*)]-(1-{1-[Imino-(3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl-  
40 sulfonylamino)-methyl]-piperidin-3-ylmethyl)-  
2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid  
tert-butyl ester;

(S)-[2-{3-[Imino-(4-methoxy-2,3,6-trimethyl-  
benzenesulfonylamino)-methyl]-phenyl}-1-(thiazole-  
2-carbonyl)-ethyl]-carbamic acid tert-butyl ester;

(S)-[2-{3-[Imino-(3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)-  
sulfonylamino)-methyl]-phenyl}-1-(thiazole-  
2-carbonyl)-ethyl]-carbamic acid tert-butyl ester;

-94-

50 1,1-dimethylethyl (S)-[4-[[imino[[ (4-methoxy-  
2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-  
amino]-1-[(1-methyl-1H-imidazol-2-yl)carbonyl]-  
butyl]carbamate; and

55 1,1-dimethylethyl (S)-[4-[[imino-  
[[ (3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzo-  
pyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(1-methyl-1H-imidazol-2-yl)carbonyl]butyl]-  
carbamate.

20. A compound selected from the group consisting of:

1,1-dimethylethyl (R)-[4-[[imino[[ (4-methoxy-  
2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-  
amino]-1-[(2-thiazolyl)carbonyl]butyl]carbamate;

5 1,1-dimethylethyl (R)-[4-[[imino-  
[[ (3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzo-  
pyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(2-thiazolyl)carbonyl]butyl]carbamate;

10 1,1-dimethylethyl (R)-[4-[[imino[[ (4-methoxy-  
2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-  
amino]-1-[(1-methyl-1H-benzimidazol-2-yl)-  
carbonyl]butyl]carbamate;

15 1,1-dimethylethyl (R)-[4-[[imino-  
[[ (3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzo-  
pyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(1-methyl-1H-benzimidazol-2-yl)carbonyl]butyl]-  
carbamate;

20 1,1-dimethylethyl (R)-[1-[(2-benzisothia-  
zolyl)carbonyl]-4-[[imino[[ (4-methoxy-2,3,6-tri-  
methylphenyl)sulfonyl]amino]methyl]amino]butyl]-  
carbamate;

25 1,1-dimethylethyl (R)-[1-[(2-benzisothia-  
zolyl)carbonyl]-4-[[imino[[ (3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)-  
sulfonyl]amino]methyl]amino]butyl]carbamate;



1,1-dimethylethyl (R)-[4-[[imino[[ (4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-amino]-1-[(2-pyridinyl)carbonyl]butyl]carbamate;

30 1,1-dimethylethyl (R)-[4-[[imino-  
[[ (3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(2-pyridinyl)carbonyl]butyl]carbamate;

35 [R-(R\*,S\*)]-(1-(1-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-methyl]-piperidin-3-ylmethyl)-2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid tert-butyl ester;

40 [R-(R\*,S\*)]-(1-(1-[Imino-(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl-sulfonylamino)-methyl]-piperidin-3-ylmethyl)-2-oxo-2-thiazol-2-yl-ethyl)-carbamic acid  
tert-butyl ester;

(R)-[2-(3-[Imino-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-methyl]-phenyl)-1-(thiazole-2-carbonyl)-ethyl]-carbamic acid tert-butyl ester;

45 (R)-[2-(3-[Imino-(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)-sulfonylamino)-methyl]-phenyl)-1-(thiazole-2-carbonyl)-ethyl]-carbamic acid tert-butyl ester;

50 1,1-dimethylethyl (R)-[4-[[imino[[ (4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]methyl]-amino]-1-[(1-methyl-1H-imidazol-2-yl)carbonyl]-butyl]carbamate; and

55 1,1-dimethylethyl (R)-[4-[[imino-  
[[ (3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)sulfonyl]amino]methyl]amino]-1-  
[(1-methyl-1H-imidazol-2-yl)carbonyl]butyl]-  
carbamate.

21. A compound selected from the group consisting of:

(S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)-  
pentyl]amino]iminomethyl]-4-methoxy-2,3,6-tri-  
methyl-benzenesulfonamide;

5 (S)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)-  
pentyl]amino]iminomethyl]-3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-  
6-sulfonamide;

10 (S)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-  
2-yl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-  
2,3,6-trimethylbenzenesulfonamide;

15 (S)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-  
2-yl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfon-  
amide;

(S)-N-[[[4-amino-5-(2-benzisothiazolyl)-  
5-oxopentyl]amino]iminomethyl]-4-methoxy-  
2,3,6-trimethylbenzenesulfonamide;

20 (S)-N-[[[4-amino-5-(2-benzisothiazolyl)-  
5-oxopentyl]amino]iminomethyl]-3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfon-  
amide;

25 (S)-N-[[[4-amino-5-(2-pyridinyl)-5-oxo-  
pentyl]amino]iminomethyl]-4-methoxy-2,3,6-tri-  
methylbenzenesulfonamide;

(S)-N-[[[4-amino-5-(2-pyridinyl)-5-oxo-  
pentyl]amino]iminomethyl]-3,4-dihydro-  
2,2,5,7,8-pentamethyl-2H-1-benzopyran-  
6-sulfonamide;

30 [S-(R\*,R\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-  
2-yl-propyl)-piperidin-1-yl]-imino-methyl)-  
4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

35 [S-(R\*,R\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-  
2-yl-propyl)-piperidin-1-yl]-imino-methyl)-  
3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-  
6-sulfonamide;

(S)-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-phenyl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

(S)-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-phenyl]-imino-methyl)-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

(S)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide; and

(S)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide.

22. A compound selected from the group consisting of:

(R)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)-pentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

(R)-N-[[[4-amino-5-oxo-5-(2-thiazolyl)-pentyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

(R)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide;

(R)-N-[[[4-amino-5-(1-methyl-1H-benzimidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

(R)-N-[[[4-amino-5-(2-benzisothiazolyl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide;

(R)-N-[[[4-amino-5-(2-benzisothiazolyl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-

-98-

2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

25 (R)-N-[[[4-amino-5-(2-pyridinyl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide;

(R)-N-[[[4-amino-5-(2-pyridinyl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

30 [R-(R\*,R\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

35 [R-(R\*,R\*)]-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-piperidin-1-yl]-imino-methyl)-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

(R)-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-phenyl]-imino-methyl)-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

40 (R)-N-([3-(2-Amino-3-oxo-3-thiazol-2-yl-propyl)-phenyl]-imino-methyl)-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide;

45 (R)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-4-methoxy-2,3,6-trimethylbenzenesulfonamide; and

(R)-N-[[[4-amino-5-(1-methyl-1H-imidazol-2-yl)-5-oxopentyl]amino]iminomethyl]-3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonamide.

50

23. A method of using a compound of Claim 14 as an intermediate for the preparation of inhibitors of serine proteases.

24. A method according to Claim 23 for the preparation of inhibitors of serine proteases involved in the blood coagulation cascade.
25. A method according to Claim 23 for the preparation of inhibitors of thrombin, Factor Xa, and Factor VIIa.

PCT/US 97/09496

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D277/28 C07D417/12 C07D417/06 C07D277/60 C07D277/64  
C07D233/54 C07D213/38 C07D235/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANGEWANDTE CHEMIE INTERNATIONAL EDITION., vol. 33, no. 17, 1994, WEINHEIM DE, pages 1729-1731, XP002040479 JINGEN DENG ET AL: "Synthesis of cyclotheonamide B and its derivatives" see the whole document ---	1
A	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 114, no. 16, 29 July 1992, DC US, pages 6570-6571, XP002040480 MASAHIKO HAGIHARA ET AL: "Reassignment of stereochemistry and total synthesis of the thrombin inhibitor cyclotheonamide B" see the whole document --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

11 September 1997

Date of mailing of the international search report

19.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Henry, J

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 30035 A (MOLECUMETICS LTD) 3. October 1996 see page 92 - page 95 see page 132 - page 133 ---	1
P,X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 16, 2 August 1996, WASHINGTON US, pages 3039-3043, XP002040481 MICHAEL J. COSTANZO ET AL: "Potent thrombin inhibitors that probe the S1'subsite:tripeptide transition state analogues based on a heterocycle-activated carbonyl group" see the whole document -----	1

**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: **1-18, 23-25**  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
The formulation of the claims is so complicated, because of the distinct combination of the meaning of the variable parts, that it does not comply with Art.6 PCT prescribing that the claims shall be clear and concise. For these reasons the search has been limited to the examples.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9630035 A	03-10-96	AU 5371496 A	16-10-96
		AU 5372996 A	16-10-96
		WO 9630396 A	03-10-96
-----			

